Cumulative Index 1981, 1982, and 1983

Volumes 65, 66, and 67

Note: The volume year is in *italic* type. Page numbers of symposium and article titles are in **boldface** type.

SYMPOSIA

1981

January ACUTE MEDICAL ILLNESS

March BODY FLUID AND ELECTROLYTE DISORDERS

Mau Obstructive Lung Diseases

July Prostaglandins September Clinical Allergy

November Gastrointestinal Motility Disorders

1982

January Antimicrobial Therapy

March LIPID DISORDERS

May Intestinal Infections

July TREATMENT OF SKIN DISEASES

September Clinical Pharmacology of Symptom Control

November Diabetes Mellitus

1983

January Infections in Office Practice
March Clinical Geriatric Medicine

May RESPIRATORY FAILURE
July ACID-BASE DISORDERS
September MEDICAL VIROLOGY
November CRITICAL CARE MEDICINE

ABELSON's disease, 1983: Sept., 1107–1108 Abetalipoproteinemia, normotrigylceri-

demic, 1982: March, 473–474 recessive, 1982: March, 469–472

Acetaminophen, overdose, management of, 1983: Nov., 1286

Acetazolamide, 1981: March, 292

in metabolic alkalosis, 1983: May, 653-654

Acetylsalicylic acid, as prostaglandin synthesis inhibitor, 1981: July, 737–742,

745-748

intoxication, 1981: March, 326 overdose, management of, 1983: Nov.,

1285-1286

urticaria and, 1982: July, 834-835 Achalasia, 1981: Nov., 1243-1247

1361

Acid(s). See also under specific acid. excretion of, in renal failure, 1983: July, 852–853

regulation of, 1983: July, 846–849 Acid-base balance, ammonia and, 1983: July, 781–798

disorders, clinical approach to, 1983: July, 799–813

in respiratory failure, 1983: May, 645-656

mixed, 1981: March, 347–361; 1983: July, 807–808

potassium concentration and, 1981: March, 364

simple, 1981: March, 321–346 simple vs. mixed, 1983: July, 800–802 symposium on, 1983: July, 751–928

in chronic renal failure, 1981: March, 437 normal regulation of, 1983: July, 771–780 renal potassium excretion and, 1981: March, 372

Acidification, distal, defects of, 1983: July, 864–870

urinary, aldosterone and, 1983: July, 880–881

ammonium excretion and, 1983: July, 790-794

in renal tubular acidosis, 1983: July, 860–862

mechanisms of, 1983: July, 753-770, 847

Acidification tests, urinary, in renal tubular acidosis, 1983: July, 861–862 interpretation of, 1983: July, 791–794

interpretation of, 1983: July, 791–79. Acidosis, chronic renal failure and, 1983: July, 845–858

hyperchloremic metabolic, 1983: July, 806–807

in renal failure, 1983: July, 853

lactic, 1983: July, 815–829 metabolic, 1981: March, 321–333 ammoniagenesis and, 1983: July, 784–787

clinical approach to, 1983: July, 804-808

renal tubular, 1983: July, 859–878 distal vs. proximal, 1983: July, 862–864, 871

respiratory, 1981: March, 337–341; 1983: May, 645–647; 1983: July, 810–811, 922–926

ammoniagenesis and, 1983: July, 784–787

in asthma, 1983: May, 678 simple vs. mixed, 1983: July, 923-924

Acne rosacea, 1982: July, 822–826 Acne vulgaris, 1982: July, 851–871

Acquired immune deficiency syndrome (AIDS), pneumonia and, 1983: Nov., 1246

viruses and, 1983: Sept., 1078, 1098-1100

Acycloguanosine. See Acyclovir.

Acyclovir, in herpes genitalis, 1983: Jan., 227–228; 1983: Sept., 1166–1167

in herpes simplex infection, 1982: July, 809

in herpes zoster infection, 1982: July, 811-812

in immunocompromised host, 1983: Sept., 1087–1088

in viral infections, 1982: Jan., 240–241 Addiction, to narcotics, 1982: Sept.,

Addiction, to narcotics, 1982: Sept., 1101–1102 Addison's disease, 1981: March, 261, 378;

1983: July, 882 crisis, 1983: Nov., 1205-1206

Adenitis, mesenteric, due to Yersinia infection, 1982: May, 644

Adenovirus(es), 1982: May, 587–588 Adenovirus infection(s), gastroenteric, 1983: Sept., 1046–1047

nosocomial, 1983: Sept., 1019 ocular, 1983: Sept., 986–987 respiratory, 1983: Sept., 1009–1011

Adenovirus vaccine, 1983: Sept., 1020 Adrenal crisis, 1983: Nov., 1205–1206 Adrenal glands, disorders, in aged, 1983:

March, 482–484 hormones. See specific hormones.

steroids. See Corticosteroid(s). Adrenal insufficiency, hyponatremia due to, 1981: March, 261

Adrenalin. See *Epinephrine*. Adrenocortical hormone. See

Corticosteroid(s). Adrenocorticosteroid(s). See Corticosteroid(s).

Adrenogenital syndrome, 1983: July, 893–894

Adult respiratory distress syndrome. See Respiratory distress syndrome, adult.

Adverse reactions, to antibiotics, 1983: Jan., 113–129

Aerosol bronchodilators, 1981: May, 585 Affective disorders, in aged, 1983: March, 366–368

Agammaglobulinemia, Bruton type, 1981: Sept., 962

Age, analgesia and, 1982: Sept., 1079–1089 herpes zoster and, 1982: Sept., 1106 pharmacokinetics and, 1982: Sept., 1073–1078

Aged, medical care of, symposium on, 1983: March, 263–543. See also under specific diseases.

Aging, effect on pharmacokinetics, 1983: March, 315–331

immune system and, 1983: March, 263–272

nutrition and, 1983: March, 295–313 A-I_{Milano} disease, 1982: March, 478

AIDS, pneumonia and, 1983: Nov., 1246

AIDS (Continued)

viruses and, 1983: Sept., 1078, 1008–1100

Airflow obstruction, chronic, sleep disorders in, 1981: May, 549–561

Airway(s), artificial, in acute respiratory failure, 1983: May, 663-664

cells, in smokers, 1981: May, 668 changes, smoking and, 1981: May,

667-689

establishment of, in acute respiratory failure, 1983: May, 661-663

hyperreactivity, in asthma, 1981: Sept., 1024–1026

inflammation, bronchial reactivity and, 1981: May, 480

obstruction, in acute respiratory failure, 1983: May, 657–668

in occupational lung disease, 1981: May, 691–706

physiology of, 1981: May, 458 respiratory muscle fatigue and, 1983:

May, 585–587 reversible, eosinophils and, 1981: Sept.,

reactivity, occupational exposure and,

1981: May, 695 respiratory infection and, 1981: Sept.,

1045–1053 responsiveness, chronic airway obstruction

and, 1981: May, 473–487 secretions, in chronic obstructive pulmo-

secretions, in chronic obstructive pulmonary disease, 1981: May, 636–638

Albuterel, 1981: May, 585

Alcohol, effect on high density lipoprotein levels, 1982: March, 414

effect on lipid metabolism, 1982: March, 497–498

Aldosterone, deficiency of, 1983: July, 881–890

renal effects of, 1983: July, 879–881 Aldosteronism, primary, 1983: July, 891–893 secondary, 1983: July, 895–898

Alginic acid, for gastroesophageal reflux, 1981: Nov., 1227–1228

Alkali therapy, in acidosis of renal failure, 1983: July, 855

in lactic acidosis, 1983: July, 825–826 in renal tubular acidosis, 1983: July, 874–875

Alkalosis, ammoniagenesis and, 1983: July, 785–786

following bicarbonate therapy, 1983: July, 910

following diuretic therapy, 1983: July, 911 gastric, 1983: July, 910–911

hyperaldosteronism and, 1983: July, 912 metabolic, 1981: March, 333–337; 1983: July, 808–810, 903–914

posthypercapnic, 1983: May, 652–654; 1983: July, 911–912

Alkalosis (Continued)

respiratory, 1981: March, 341–345; 1983: May, 645–647; 1983: July, 810–811, 917–922

simple vs. mixed, 1983: July, 919–920 Allergic disorders, corticosteroids for, 1981: Sept., 1073–1081

immunotherapy of, 1981: Sept., 987-1012

Allergic reactions. See also Hypersensitivity. late phase, 1981: Sept., 955 to drugs, 1981: Sept., 1089-1103 to penicillin, 1983: Jan., 114-121 to vaccines, 1983: Jan., 22-23

Allergic rhinitis, 1981: Sept., 977-986 immunotherapy for, 1981: Sept., 983, 988-990

Allergoid, 1981: Sept., 984 Allopurinol, 1981: March, 409

Alpha-adrenergic blocking agents, effects, in diabetics, 1982: Nov., 1382

Alupent. See Metaproterenol.

Alveolar macrophages, of smokers, 1981: May, 668, 679-683

Alzheimer's disease, in aged, 1982: Sept., 1144–1146; 1983: March, 351, 363–364

Amantadine, for viral respiratory infections, 1982: Jan., 237–238; 1983: Sept., 1021, 1167–1169

Aminocyclitol(s), resistance to, 1982: Jan., 32-33

Aminoglycoside(s), 1982: Jan., 303–312 disposition of in liver disease, 1982: Jan., 264

resistance to, 1982: Jan., 32–33, 303–304 Amitryptyline, for depression, 1982: Sept., 1037–1045

Ammonia, acid-base balance and, 1983: July, 781–798

excretion of, 1983: July, 848 in hypoaldosteronism, 1983: July, 886 in renal failure, 1983: July, 851–852 production of, aldosterone and, 1983:

July, 881 potassium balance and, 1983: July, 787–790

transport into urine, 1983: July, 790 Amoebiasis, 1982: May, 689–705 cutaneous, 1982: May, 697 extraintestinal, 1982: May, 695–697 intestinal, 1982: May, 692–695 metronidazole for, 1982: Jan., 124 nondysenteric, treatment, 1992: May,

709-710 treatment, 1982: May, 707-710

Amoebomas, 1982: May, 694 treatment, 1982: May, 712

Amoxicillin, 1983: Jan., 63-64 Amphotericin B, for fungal infections, 1982: Jan., 222-227; 1983: July, 890-891

Ampicillin, 1983: Jan., 63 for shigellosis, 1982: May, 634 Amyloidosis, senile cardiac, 1983: March, 392

Anal fissure, 1981: Nov., 1384–1385 Analgesia, in the elderly, 1982: Sept.,

1079–1089 in the terminally ill, 1982: Sept., 1179–1182

narcotic, 1982: Sept., 1091–1104 pharmacology of, 1982: Sept., 1061–1071

with nonsteroidal anti-inflammatory drugs, 1982: Sept., 1053–1059

Anaphylactic reactions, 1981: Sept., 941 to drugs, 1981: Sept., 1092

Anaphylaxis, 1981: Jan., 227-235 eosinophil chemotactic factor of, 1981: Sept., 951

penicillin-induced, 1983: Jan., 116–118 slow-reactive substance of, in immediate hypersensitivity, 1981: Sept., 953

Ancylostoma duodenale infection, 1982: May, 731–733

Anemia, hemolytic, drug-induced, 1981: Sept., 1097; 1983: Jan., 122 in acute respiratory failure, 1983: May,

in aged, 1983: March, 304–305 megaloblastic, in aged, 1983: March, 305–306

Anesthesia, in diabetics, 1982: Nov., 1363 Aneurysm, arterial, 1981: Jan., 83–103

dissecting, 1981: Jan., 94–102
 Angiitis, treatment of, 1982: July, 941–954
 urticarial, 1982: July, 836–840

Angiodysplasia, bleeding from, 1983: Nov., 1226–1227

Angiography, in gastrointestinal hemorrhage, 1983: Nov., 1219 in pulmonary embolism, 1983: Nov., 1185 Angiotensin, prostaglandins and, 1981: July,

Anion gap, elevated, acidosis with, 1981: March, 326

in acid-base disorders, 1983: July, 803–804

in ketoacidosis, 1983: July, 836–837 in metabolic acidosis, 1983: July, 805 in mixed acid-base disorders, 1981:

March, 354
Anorexia, in aged, 1983: March, 337
in terminally ill, 1982: Sept., 1174
Antacid(s), in prophylaxis of stress ulcers,

1983: Nov., 1224–1225 in reflux esophagitis, 1981: Nov., 1224, 1226–1227

Anthralin, in psoriasis, 1982: July, 781 Anthranilic acid(s), for pain, 1982: Sept., 1057–1058

Antiarrhythmic drug(s), in aged, 1983: March, 324–325 Antibiotic-associated pseudomembranous colitis, 1982: May, 655-664

Antibiotic(s), adverse reactions to, 1983: Jan., 113–129

for acne, 1982: July, 858-861

for respiratory tract infections, 1983: Jan., 162–163

for urinary tract infections, 1983: Jan., 193 for secretory diarrhea, 1982: May, 616–617

for shigellosis, 1982: May, 633–635 for Yersinia enteritis, 1982: May, 647–650 in aged, 1983: March, 285–287

in chronic bronchitis and emphysema, 1983: May, 663

Antibody-dependent cell-mediated cytotoxicity, 1981: Sept., 943

Antibody(ies), viral monoclonal, 1983: Sept., 963 Antibody assays, in diagnostic virology,

1983: Sept., 945–946, 956–965 in herpes simplex encephalitis, 1983: Sept., 994–996

Antidepressant drugs, in aged, 1983: March, 371–374

overdose, management of, 1983: Nov., 1287–1288

Antidiarrheal agents, 1983: Jan., 211–213 Antidiuretic hormone, secretion, inappropriate, syndrome of, 1981: March, 265

mechanisms of, 1981: March, 254 Antielastase system, emphysema and, 1981: May, 651

Antifungal agents, in fungal infection, 1982: July, 875–876

Antigen(s). See also specific antigens. HLA, diabetic complications and, 1982: Nov., 1217–1218 in diabetes, 1982: Nov., 1195–1196, 1210–1212

Antihistamines, dermatitis from, 1981: Sept., 1084 for pruritus, 1982: Sept., 1124

for urticaria, 1982: July, 838–839 Antihypertensive drug(s), effects, in diabetics, 1982: Nov., 1379–1387

in aged, 1983: March, 325, 410–412 Antihypertensive therapy, in aged, 1983: March, 405–412

Anti-inflammatory agent(s), as prostaglandin inhibitors, 1981: July, 713–757 for herpes zoster, 1982: Sept., 1113 for osteoarthritis, 1983: March, 528–529 nonsteroidal, for pain, 1982: Sept.,

1053–1059

Antimalarial agent(s), for cutaneous lupus erythematosus, 1982: July, 803

Antimetabolite(s), systemic, in psoriasis, 1982: July, 785–787

Antimicrobial drug(s), comparative costs, 1983: Jan., 174

in enteric infections, 1983: Jan., 214–216 oral, 1983: Jan., 57–98. See also specific drug, as *Penicillin*.

outpatient use, 1983: Jan., 3-16 prophylactic, 1983: Jan., 99-112

Antimicrobial therapy, administration of, 1982: Jan., 9–10

choosing of appropriate agent, 1982: Jan., 6–9

combination, 1982: Jan., 17–24 liver disease and, 1982: Jan., 257–266 monitoring, 1982: Jan., 10–11

principles of, 1982: Jan., 3–15 renal insufficiency and, 1982: Jan., 267–281

resistance to, 1982: Jan., 25-37

Antimonials, for parasitic infections, 1982: Jan., 249 Antimycotic agent(s), in dermatomycoses,

1982: July, 887–893 Antipseudomonas penicillins. See specific

agent, such as Carbenicillin.
Antipsychotic drug(s), 1982: Sept., 993-1009

in aged, 1983: March, 370–371 Antisera, viral, 1983: Sept., 962–963

Antistaphylococcal penicillin(s), 1982: Jan., 51-60. See also Penicillins, antistaphylococcal.

Antituberculous agent(s), 1983: Jan., 80–83 Antiviral drug(s). See *Drug(s)*, antiviral or under specific agent, as *Vidarabine*.

Antiviral therapy, 1982: Jan., 235–244 Anxiety, in aged, 1982: Sept., 1014 1983: March, 368

in terminally ill, 1982: Sept., 1016, 1177

with acute illness, 1981: Jan., 5 Aorta, aneurysms of, 1981: Jan., 83–91 dissection, pain of, 1981: Jan., 59

Apnea, sleep, 1981: May, 558; 1982: Sept., 980–982

in aged, 1983: March, 424 with high-frequency ventilation, 1983: May, 638

Apoplexy, pituitary, 1981: Jan., 105–116
 Apoprotein B, overproduction, in hypertriglyceridemia, 1982: March, 523–525

Apoprotein E phenotypes, prevalence in population, 1982: March, 445–447

Apoprotein E polymorphism, biochemical genetics, 1982: March, 442–446

Appendix, ulcerations, due to Yersinia infection, 1982: May, 644

Ara-A. See Vidarabine.

Arachidonic acid, metabolism of, 1983: May, 719

in platelet-vessel wall interactions, 1981: July, 855-880 Arachidonic acid (Continued)

in prostaglandin synthesis, 1981: July, 716-720

metabolites, as mediators of hypersensitivity and inflammation, 1981: July, 809–828

ARDS. See Respiratory distress syndrome, adult.

Arrhythmia(s). See also specific disorders. cardiac, chronic airflow obstruction and, 1981: May, 554

in aged, 1983: March, 387-390 ventricular, in acute respiratory f

ventricular, in acute respiratory failure, 1983: May, 735

Arteritis, temporal, 1982: July, 952 in aged, 1982: Sept., 1051

Arthritis, acute, 1981: Jan., 177–188 digital, in psoriasis, 1982: July, 773–774 in aged, 1982: Sept., 1047–1052 rheumatoid. See Rheumatoid arthritis.

Articulation. See *Joint*. Ascariasis, drug therapy for, 1982: May, 724–729

Aspergillosis, bronchopulmonary, allergic, 1981: Sept., 1041, 1061–1063 Aspergillus pneumonia, 1983: Nov.,

1244–1245 Aspirin. See Acetylsalicylic acid.

Asthma, 1981: May, 456 acute, 1983: May, 669–684 airway hyperreactivity in, 1981: Sept.,

1024–1026 assessment of, 1981: Sept., 1033–1036 bronchial reactivity and, 1981: May, 475 bronchoconstriction of, 1981: Sept., 1015 control of, 1981: Sept., 1033–1043 corticosteroids in, 1981: Sept., 1059 drug therapy for, 1981: May, 579–613 eosinophilia in, 1981: Sept., 1058 immunotherapy for, 1981: Sept., 990–993

mast cells in, 1981: Sept., 1015–1018 medications for, 1981: Sept. 1038–1040 neurogenic mechanisms in, 1981: Sept., 1023

occupational, 1981: May, 697–700 pathogenesis and pathophysiology of, cellular mechanisms in, 1981: Sept., 1013–1031

pregnancy and, 1983: May, 682 Astrovirus(es), 1982: May, 587–588 Astrovirus infection(s), gastroenteric, 1983: Sept., 1047

Ataxia telangiectasia, 1981: Sept., 966 Atelectasis, radiographic features of, 1983: Nov., 1321

Atherogenesis, arachidonic acid metabolism and, 1981: July, 867–870

Atherogenic hyperlipoproteinemia, 1982: March, 375–402 Atherosclerosis, high density lipoproteins and, 1982: March, 331, 390

in diabetics, 1982: Nov., 1347–1348
in dogs, β-very low density lipoproteins and, 1982: March, 393–395

in familial dysbetalipoproteinemia, 1982: March, 450–451

in hyperlipidemia, 1982: March, 331 LDL stimulation of cell growth and, 1982: March, 397

low density lipoproteins and, 1982: March, 395–396

macrophage accumulation hypothesis, 1982: March, 396–397

pathogenetic models, 1982: March, 377 plasma triglycerides and, 1982: March, 519–522

Athlete's foot, 1982: July, 878

Atopic disorders, immunotherapy of, 1981: Sept., 987–1012

adverse reactions to, 1981: Sept., 1002 selecting patients for, 1981: Sept., 998–1000

Autoimmune disorder(s). See also specific disorders, as *Myasthenia gravis*. diabetes and, 1982: Nov., 1215–1217

renal tubular acidosis and, 1983: July, 872 Autosensitization, immunodeficiency and, 1981: Sept., 960

Azlocillin, 1982: Jan., 61-73

Azotemia, prerenal, 1981: March, 414

BACAMPICILLIN, 1983: Jan., 64–65 Bacillus Calmette-Guerin, prostaglandins and, 1981: July, 836

Bacillus cereus, enterotoxigenic, 1982: May, 605

Bacitracin, for antibiotic-associated pseudomembranous colitis, 1982: May, 660-661

Bacteria, antibiotic-resistant, control of in hospitals, 1982: Jan., 34–35

Bacterial infection(s), in aged, 1983: March, 273–287

Bacterial intestinal infection, in immunocompromised patient, 1982: May, 747

Bacterial overgrowth syndromes, 1982: May, 563-567

Bacterial pneumonia(s). See specific pathogens.

Bacteriuria, asymptomatic, 1983: Jan., 195 in aged, 1983: March, 284–285, 452–453 Balantidium coli infection, treatment, 1982: May, 713

Balloon tamponade, for variceal bleeding, 1983: Nov., 1220–1221

Barbiturates, overdose, management of, 1983: Nov., 1288–1289 Barotrauma, pulmonary, in acute respiratory failure, 1983: May, 694-695, 727-728

Bartter's syndrome, 1981: March, 383; 1983: July, 895–898

prostaglandins and, 1981: July, 897–901 Base(s). See Ammonia; Bicarbonate.

Basophils, in immediate hypersensitivity reactions, 1981: Sept., 945–950

Beal's disease, 1983: Sept., 986-987

B-cell deficiency syndromes, 1982: May, 744–746

Beclomethasone, 1981: Sept., 1077 Behavioral therapy, in gastrointestinal dis-

eases, 1981: Nov., 1397–1411 Benoxaprofen, for pain, 1982: Sept., 1057

Benzocaine, dermatitis from, 1981: Sept., 1084

Benzodiazepine(s), in aged, 1982: Sept., 1017–1035; 1983: March, 374–375

Benzolamide, 1981: March, 292 Benzoyl peroxide, dermatitis from, 1981:

Sept., 1085 for acne, 1982: July, 857-858

Beta-adrenergic drug(s), effects, in diabetics, 1982: Nov., 1382–1383

for asthma, 1981: Sept., 1038 Beta₂-agonists, 1981: May, 580-585 in cor pulmonale, 1981: May, 514

Beta-lactam antibiotic(s), resistance to, 1982: Jan., 28–31

Betamethasone, for asthma, 1981: May, 602 Bethanechol, for gastroesophageal reflux,

1981: Nov., 1228 Bicarbonate, concentration, in respiratory failure, 1983: May, 645–656

PCO₂ and, in regulation of pH, 1983: July, 800

in respiratory alkalosis, 1983: July, 917–922

renal reabsorption of, 1981: March, 334; 1983: July, 753–768, 846–847 in metabolic alkalosis, 1983: July, 905–906 in renal failure, 1983: July, 849–850

in renal tubular acidosis, 1983: July, 860–862

nephron sites of, 1983: July, 763–767 serum, in mixed acid-base disorders, 1981: March, 352–355

Bicarbonate buffer system, 1983: July, 773 Bicarbonate-chloride exchange mechanisms. 1983: July, 762–763

Bicarbonate therapy, alkalosis and, 1983: July, 910–911

in ketoacidosis, 1983: July, 840–841; 1983: Nov., 1194–1195

in lactic acidosis, 1983: July, 825–827 Biguanides, lactic acidosis and, 1983: July, 822–823

Bile-acid binding resins, for hypercholesterolemia, 1982: March, 540-542 Biliary tract, disorders, in aged, 1983: March, 436

infections, cephalosporins for, 1982: Jan., 189–191

Biopsy. See also under specific organ or procedure.

of brain, in herpes simplex encephalitis, 1983: Sept., 998–1001

Bithionol, for parasitic infections, 1982: Jan., 250

Bladder, bacteriuria of, antimicrobials for, 1982: Jan., 206

neurogenic, in aged, 1983: March, 457–458

Blastomycosis, South American, 1982: May, 680–683

Bleeding. See Hemorrhage.

Blepharitis, 1983: Jan., 133-138

Blood, elements. See specific elements, as *Platelets*.

Blood gases, arterial, in acid-base disorders, 1983: July, 804

in acute respiratory failure, 1983: May, 557–571

in evaluation of asthma, 1983: May, 672–673

in evaluation of mechanical ventilation, 1983: May, 614–619

Blood glucose, as measure of diabetic control, 1982: Nov., 1255–1260

control, during pregnancy, fetal malformations and, 1982: Nov., 1333-1335 during surgery, 1982: Nov., 1361-1372 glycosylated hemoglobin and, 1982: Nov., 1309-1315

measurements, in diagnosis of diabetes, 1982: Nov., 1199–1200

meticulous control of, 1982: Nov., 1317-1324

during pregnancy, 1982: Nov., 1329-1333

self-monitoring of, 1982: Nov., 1227–1250, 1259–1260, 1320

in patient education, 1982: Nov., 1302–1303

target levels, in diabetics, 1982: Nov., 1228

Blood platelets. See Platelets.

Blood pressure, continuous monitoring of, in critically ill, 1983: Nov., 1345–1348 elevated. See Hypertension. low. See Hypotension.

Blood sampling, techniques, in diabetes, 1982: Nov., 1228–1229

Blood vessels, arachidonic acid metabolites and, 1981: July, 815 arachidonic acid metabolism in, 1981:

July, 858

Body water, balance, in chronic renal failure, 1981: March, 435 Body water (Continued)

loss, 1981: March, 274-277

in ketoacidosis, 1983: July, 837 renal excretion of, 1981: March, 256-259

Body weight, diabetes and, 1982: Nov., 1196

Bone, buffering by, 1983: July, 777–778 disease, in aged, 1983: March, 356, 517– 524

infections, cephalosporins for, 1982: Jan., 186-188

loss, age-related, 1983: March, 518 nutritional status and, 1983: March, 301–303

skeletal, age-related changes, 1983: March, 517–518

Bone resorption, prostaglandins and, 1981: July, 846

Botulism, 1981: Jan., 198

Bowel. See also Intestine(s).

disorders, in aged, 1983: March, 436 motility, 1981: Nov., 1377–1396

inflammatory disease, in aged, 1983: March, 442-443

irritable, syndrome of, 1981: Nov., 1386–1391

behavioral therapy, 1981: Nov., 1402–1404

obstruction of, in aged, 1983: March, 437–438

Bowen's disease, in aged, 1983: March, 539
 Brain, trauma to, 1981: Jan., 20
 tumors, 1981: Jan., 21–25
 viral infection of, 1983: Sept., 991–1008

Breast, cancer of, RNA viruses and, 1983. Sept., 1110

Breathing. See also Respiration; Ventilation. disordered, in aged, 1983: March, 422–425 intermittent positive-pressure, 1983: May, 627

Breathing patterns, abnormalities, in chronic airflow obstruction, 1981: May, 557

Breathing retraining. 1981: May, 640 Bronchial asthma. See Asthma.

Bronchial reactivity, 1981: May, 456. See also Airway responsiveness.

Bronchial sensitivity, immunotherapy and 1981: Sept., 990

Bronchitis, 1981: May, 456; 1983: Jan., 181 chronic, acute respiratory failure in, 1983: May, 657–668

airway reactivity in, 1981: May, 476–478, 483

infection and, 1981: May, 685 left ventricular performance in, 1981:

May, 508–510 pathogenesis of, 1981: May, 656–661

right ventricular hemodynamics in. 1981: May, 501–505

viral, 1983: Sept., 1016-1017

Bronchoconstriction, in asthma, 1981: Sept., 1015

Bronchodilator(s), in asthma, 1983: May, 676–677

in chronic bronchitis and emphysema, 1983: May, 661-663

in hospitalized asthmatics, 1983: May, 680 sympathomimetic, 1981: May, 580–587 Bronchospasm, 1981: May, 456

in chronic obstructive lung disease, 1981: May, 569

Brucellosis, rifampin for, 1982: Jan., 161 Bruton agammaglobulinemia, 1981: Sept.,

Bruton's syndrome, 1982: May, 745

Buffer systems, in acid-base balance, 1983: July, 771–780

of extracellular fluids, 1983: July, 775–776 Buffering, extrarenal, in renal failure, 1983: July, 853–854

isohydric, 1983: July, 774-775

Burkitt's lymphoma, Epstein-Barr virus and, 1983: Sept., 1115–1117

Butorphanol, for pain, 1982: Sept., 1063, 1096

CALCINOSIS, tumoral, 1981: March, 397 Calcitonin, 1981: March, 388

Calcium, balance, in chronic renal failure, 1981: March, 439, 442

1981: March, 439, 442 disorders, 1981: March, 385–392

severe, 1983: Nov., 1206–1210 in basophil and mast cell release, 1981: Sept., 950

metabolism, in acute tubular necrosis, 1981: March, 424

in aged, 1983: March, 492

Calicivirus(es), 1982: May, 587–588 Calicivirus infection(s), gastroenteric, 1983: Sept., 1048

Caloric balance, positive. See Obesity.
Calories, effect on lipid metabolism, 1982:
March, 495

Cancer. See also Carcinoma. effect of interferon on, 1983: Sept., 1156–1157

viruses and, 1983: Sept., 1105-1127 Candida albicans, in fungal enteritis, 1982: May, 675-678

Candidissis, 1983: Jan., 229–230 chronic mucocutaneous, 1981: Sept., 966 treatment of, 1982: July, 884–887

Captopril, effects, in diabetics, 1982: Nov., 1383–1384

Carbenicillin, 1982: Jan., 61-73

Carbohydrates, dietary, effect on high density lipoprotein levels, 1982: March, 412–414

> effect on lipid metabolism, 1982: March, 495–497

Carbon dioxide, bicarbonate buffer system and, 1983: July, 773

excretion, by lung, 1983: July, 915–917 partial pressure. See Pco₂.

Carbon dioxide metabolism, 1981: March, 337

Carbonic acid, bicarbonate buffer system and, 1983: July, 773

Carcinoma. See also under specific organs and types.

cutaneous, in aged, 1983: March, 537–541 gastrointestinal, in aged, 1983: March, 440–442

host defense in, prostaglandins and, 1981: July, 829–844

hypercalcemia of, prostaglandins and, 1981: July, 845–853

immunodeficiency and, 1981: Sept., 960 lactic acidosis and, 1983: July, 821–822 metastases, prostaglandins and, 1981: July, 838

of prostate, in aged, 1983: March, 448–449 of thyroid, in aged, 1983: March, 510–512 pain, morphine for, 1982: Sept., 1082–1086

Cardiac. See also Heart.

Cardiac arrhythmia(s). See Arrhythmia(s), and specific types.

Cardiac care, acute, 1981: Jan., 67-81

Cardiac output, decrease of, from end-expiratory pressure, 1983: May, 735–736

Cardiovascular complications, of acute respiratory failure, 1983: May, 695, 734–736 Cardiovascular function, effect of mechanical

ventilation on, 1983: May, 626–627 Cardiovascular performance, in obstructive lung disease, 1981: May, 489–524

Cardiovascular system, disorders, in aged, 1983: March, 379–394

in elderly hypertensives, 1983: March, 396–398

in respiratory acidosis, 1983: July, 923 in respiratory alkalosis, 1983: July, 919

Cardioversion, electrical, 1981: Jan., 67 Carotid artery, aneurysm of, 1981: Jan., 93

Cartilage, articular, age-related changes, 1983: March, 524–525

Cataplexy, imipramine for, 1982: Sept., 980 Catecholamine(s), potassium balance and, 1981: March, 367

Cathartic(s), for constipation, 1982: Sept., 1137

Catheter(s), technical considerations of, 1983: Nov., 1345–1346, 1350–1353

Catheterization, infection and, 1983: Jan., 198–199

pulmonary artery, complications of, 1983: Nov., 1356

in critically ill, 1983: Nov., 1348–1358 Swan-Ganz, in respiratory failure, complications of, 1983: May, 728 Catheterization (Continued)

systemic arterial, complications of, 1983: Nov., 1346–1347

in critically ill, 1983: Nov., 1345-1348

Cefaclor, 1983: Jan., 68 Cefadroxil, 1983: Jan., 67-68

Cefoperazone, 1982: Jan., 285–288

Cefotaxime, 1982: Jan., 284–288

Cell culture, in diagnostic virology, 1983: Sept., 936–944, 948–949, 962

Cellular immunity, assessment of, 1981: Sept., 974

Cellular mediator(s), of septic lung injury, 1983: May, 708–710

Cellulitis, orbital, 1983: Jan., 147-148 preseptal, 1983: Jan., 137

Central nervous system. See Nercous system, central.

Cephalexin, 1983: Jan., 66

Cephalosporin(s), first and second generation, 1982: Jan., 183-195

oral, adverse reactions to, 1983: Jan., 113–129

resistance to, 1982: Jan., 28–31 third generation, 1982: Jan., 283–291. See

also Cefoperazone; Cefotaxime; Moxalactam.

Cephradine, 1983: Jan., 67

Cerebellar ataxia, progressive, 1981: Sept., 966

Cerebral edema, diabetic ketoacidosis and, 1981: Jan., 131

in overdose patient, 1983: Nov., 1282–1283

with fulminant hepatic failure, 1981: Jan., 223

Cerebrovascular disease, in aged, 1983: March, 354–355

Cervical secretions, laboratory examination, 1983: Jan., 49-51

Cervicitis, chlamydial, 1983: Jan., 232 gonococcal, 1983: Jan., 231–232

Cervix, cancer of, herpes simplex virus and, 1983: Sept., 1114–1115 papillomavirus and, 1983: Sept., 1118–1119

Chalazion, 1983: Jan., 135-136

Chancroid, 1982: July, 920–921; 1983: Jan., 245

Charcoal, activated, in drug elimination, 1983: Nov., 1283–1284

Chediak-Higashi syndrome, 1981: Sept., 968 Chemicals, toxic, diabetes and, 1982: Nov., 1214

Chemoprophylaxis, antimicrobial, 1983: Jan., 99–112

Chemotherapy. See also specific agents and disorders.

for warts, 1982: July, 814

in cutaneous T cell lymphoma, 1982: July, 905–908 Chest. See also *Thoracic*. pain, 1981: Jan., 53-66

physiotherapy, 1981: May, 637 radiographic examination of, in critical care medicine, 1983: Nov., 1305–1324

Cheyne-Stokes respiration, in aged, 1983: March, 424–425

Chickenpox, 1982: July, 810-812

in immunocompromised host, 1983: Sept., 1083–1084

Child(ren), asthma in, 1981: Sept., 1040 gastrointestinal bleeding in, 1983: Nov., 1228

hyperlipidemia in, diet therapy for, 1982: March, 504

immunization of, 1983: Jan., 23–29 viral gastroenteritis in, 1983: Sept., 1036–1037

Chlamydia infection(s), genital, 1983: Sept., 1065–1069

ocular, 1983: Jan., 142-143

Chlamydia pneumonia, 1983: Nov., 1241Chloramphenicol, 1982: Jan., 91–102; 1983: Jan., 69

resistance to, 1982: Jan., 33

Chloride, balance, in acid-base disorders, 1983: July, 803

in metabolic alkalosis, 1983: July, 906–909

in mixed acid-base disorders, 1981: March, 353

Chloride-bicarbonate exchange mechanisms, 1983: July, 762–763

Chloroquine, for parasitic infections, 1982: Jan., 245–246

Chloroquine phosphate, for intestinal protozoan infections, 1982: May 714–715 Chlorpropamide, 1981: March, 317

Cholecystogastric scintigraphy, 1981: Nov., 1301–1308

Cholera, 1982: May, 598–602, 611–612, 667–668

preventing, 1982: May, 618

Cholestasis, pruritus in, 1982: Sept., 1126Cholesterol, dietary, effect on lipid metabolism, 1982: March, 486–490

metabolism, role of high density lipoproteins with apo-E, 1982: March, 387–390 net transport, relation to cholesteryl ester

transfer, 1982: March, 369–371 relation to lecithin:cholesterol acyltrans-

ferase activity, 1982: March, 367–369 regulation of efflux from cells, 1982:

March, 364–366 regulation of influx into cells, 1982: March, 366–367

transport, abnormalities in hypercholesterolemia, 1982: March, 371–372

between cells and body fluids, 1982: March, 363–373 Cholesteryl ester transfer, relation to cholesterol net transport, 1982: March, 369–371

Cholestyramine, for hypercholesterolemia, 1982: March, 540–542

Cholinergic urticaria, 1982: July, 843 Chondrocalcinosis, in aged, 1982: Sept.,

Chorea, in aged, 1983: March, 356 Churg-Strauss syndrome, 1981: Sept., 1068

Chylomicron(s), 1982: March, 520 Chylomicronemia, 1982: March, 455–468

Chylomicronemia, 1982: March, 455–468 familial hypobetalipoproteinemia with, 1982: March, 474

severe, diet therapy for, 1982: March, 502–503, 515

Cimetidine, for gastroesophageal reflux, 1981: Nov., 1229–1231

in prophylaxis of stress ulcers, 1983: Nov., 1224–1225

Cinoxacin, 1983: Jan., 76-77

Cirrhosis, pruritus in, 1982: Sept., 1126

Clindamycin, 1982: Jan., 103-120; 1983: Jan., 69-70

disposition of in liver disease, 1982: Jan., 260–262

Clofibrate, 1981: March, 318

Clostridium difficile, in pseudomembranous colitis, 1982: May, 658–659

Clotrimazole, for systemic mycoses, 1982: Jan., 228–230

Clotting, blood. See Coagulation.

Cloxacillin, 1983: Jan., 62-63

Coagulation factor(s), disorders of, 1981: Jan., 138

Coccidiosis, intestinal, treatment, 1982: May, 713

Codeine, for pain, 1982: Sept., 1094 Colestipol, for hypercholesterolemia, 1982: March, 540–542

Colistimethate sodium. See Sodium colistimethate.

Colistin, 1982: Jan., 135-142

Colitis, ischemic, in aged, 1983: March, 439 pseudomembranous, 1982: May, 655–664 ulcerative, in aged, 1983: March, 442–443 Collagen, for acne, 1982: July, 867–868

Colon, cathartic, 1981: Nov., 1385 cancer of, in aged, 1983: March, 440 disorders, in aged, 1983: March, 435–436 diverticular disease of, in aged, 1983:

March, 440–442 function during sleep, 1981: Nov., 1372–1373

ulcerations, due to Yersinia infection, 1982: May, 644

Coma, 1981: Jan., 15–32 diabetic, 1981: Jan., 117–132 differential diagnosis of, 1983: Nov., 1281 hyperosmolar nonketotic, 1983: Nov., 1198–1199 Coma, hyperosmolar nonketotic (Continued) in surgical patients, 1982: Nov., 1369–1370

hypoglycemic, 1983: Nov., 1199–1202 myxedematous, 1983: Nov., 1203–1205

Combination therapy, 1982: Jan., 17-24. See also Antimicrobial therapy, combination.

Complement, in immune complex reactions, 1981: Sept., 944

in septic lung injury, 1983: May, 705–707 Complement system, disorders of, 1981: Sept., 969–970

Computed tomography, in herpes simplex encephalitis, 1983: Sept., 997–998

Concussion, 1981: Jan., 20 Condylomata acuminata, 1982: July,

Condylomata acuminata, 1982: July, 812–814; 1983: Jan., 246; 1983: Sept., 1064–1065

Confusion, in the terminally ill, 1982: Sept., 1177–1178

Confusional state, acute, 1981: Jan., 10, 15–32

Congenital defects, fetal, diabetes and, 1982: Nov., 1333–1335

Congestive heart failure, radiographic features of, 1983: Nov., 1312–1315
Conjunctivitis, bacterial, 1983: Jan., 141–142
in neonates, 1983: Jan., 143–144

viral, 1983: Jan., 139–141
Constipation, idiopathic, 1981: Nov., 1386
in aged, 1983: March, 338, 435

in aged, 1993; March, 339, 439 in terminally ill, 1982; Sept., 1175 traumatic, 1981; Nov., 1382–1383 treatment for, 1982; Sept., 1135–1139 with narcotics, 1982; Sept., 1100

Contact dermatitis, allergic eczematous, 1981: Sept., 1093

Continuous positive airway pressure. See Pressure, continuous positive airway. Contraction alkalosis, 1981: March, 333

Convulsions, in terminally ill, 1982: Sept., 1178

Cornea, infective ulcer, 1983: Jan., 144-145 Coronavirus, 1982: May, 589

Coronavirus infection(s), gastroenteric, 1983: Sept., 1047

respiratory, 1983: Sept., 1010 Cor pulmonale, 1981: May, 495-49

Cor pulmonale, 1981: May, 495–497, 638 in aged, 1983: March, 386

Corpus luteum function, prostaglandins and, 1981: July, 928

Corticosteroids, as prostaglandin synthesis inhibitors, 1981: July, 743, 749 for acne, 1982: July, 862–863, 866

for asthma, 1981: May, 599-605; 1981: Sept., 1038, 1059; 1983: May, 680

for cutaneous lupus erythematosus, 1982: July, 803

for pain, 1982: Sept., 1058 for psoriasis, 1982: July, 777-779 Corticosteroids (Continued)

in ARDS, 1983: May, 717-724

in allergic disease, 1981: Sept., 1073–1081 in chronic bronchitis and emphysema, 1983: May, 663

in septic shock, 1983: May, 717-724 topical, dermatitis from, 1981: Sept., 1086

Corynebacterium parvum, prostaglandins and, 1981: July, 836

Cough, in terminally ill, 1982: Sept., 1176 CPAP. See Pressure, continuous positive airway.

CPPV. See Ventilation, continuous positive pressure.

Cricopharyngeal diverticulum, 1981: Nov., 1256–1258

Critical care medicine, nutrition in, 1983: Nov., 1295–1304

symposium on, 1983: Nov., 1179-1360 Crohn's disease, in aged, 1983: March, 442-443

Cromoglycate, 1981: Sept., 1038

Cromolyn sodium, 1981: May, 597-599

Cromone(s), for pruritus, 1982: Sept., 1125 Cryosurgery, for warts, 1982: July, 812

Crystal deposition, arthritis and, 1981: Jan., 178–181

Cushing's disease, steroid-induced, 1981: Sept., 1075

Cushing's syndrome, 1981: Jan., 198; 1983: July, 894

Cutaneous complications, with intravenous delivery of insulin, 1982: Nov., 1281–1282

Cutaneous T cell lymphoma, treatment of, 1982: July, 895–913

Cutis. See Skin.

Cyanide, overdose, management of, 1983: Nov., 1290

Cyclacillin, 1983: Jan., 65

Cyclic 3'5'-monophosphate (cAMP), in immediate hypersensitivity reactions, 1981: Sept., 950

Cyclo-oxygenase pathway, role in sepsis, 1983: May, 703–704

Cystic fibrosis, left ventricular performance in, 1981: May, 508–510 right ventricular hemodynamics in, 1981:

May, 505–508 Cystitis, in children, trimethoprim-sulfa-

methoxazole for, 1982: Jan., 148 Cytologic examination, in diagnostic virol-

ogy, 1983: Sept., 948 Cytomegalovirus, oncogenicity of, 1983:

Sept., 1118 Cytomegalovirus infection(s), in homosexual

men, 1983: Sept., 1098–1100 in immunocompromised host, 1982: May, 748; 1983: Sept., 1079–1081 ocular, 1983: Sept., 985–986

Cytotoxic reactions, 1981: Sept., 941-943

DACRYOADENITIS, 1983: Jan., 146–147 Dacryocystitis, 1983: Jan., 146

Death and dying. See *Terminal illness*. Defecation, difficult, treatment for, 1982: Sept., 1135–1140

Deglutition. See Swallowing.

Dehydroemetine dihydrochloride, for intestinal protozoan infections, 1982: May, 715

Delirium, in aged, 1983: March, 347–348, 362–363

Delivery, timing of, in diabetic pregnancy, 1982: Nov., 1337–1341

Dementia, 1982: Sept., 1143–1160 drug-induced, in aged, 1982: Sept., 1076 in aged, 1983: March, 349–351 multi-infarct, 1982: Sept., 1146–1147 pathophysiology of, 1982: Sept., 1150–1151

senile, Alzheimer's type (SDAT), 1983: March, 363–364

treatment of, 1982: Sept., 1151-1156

Denial, of illness, 1981: Jan., 4 Dependency, reaction to acute illness, 1981:

Jan., 7 Depression, dementia and, 1982: Sept., 1148–1149

drug therapy for, 1982: Sept., 1037–1045 in aged, 1982: Sept., 1012–1014; 1983: March, 366–368

drug-induced, 1982: Sept., 1076 in terminally ill, 1982: Sept., 1015, 1177 Dermabrasion, for acne, 1982: July, 867

Dermatitis, allergic eczematous contact, 1981: Sept., 1093

exfoliative, 1981: Sept., 1098 iatrogenic, 1981: Sept., 1083–1088

perioral, from corticosteroids, 1981: Sept., 1086

treatment of, 1982: July, 819–822 seborrheic, in aged, 1983: March, 535 treatment of, 1982: July, 826–829 stasis, in aged, 1983: March, 534–535

Dermatologic disorders, in aged, 1983: March, 342, 531–543

Dermatologic reactions, to antibiotics, 1983: Jan., 118–120

Dermatology, symposium on, 1982: July, 769–963

Dermatophytoses, treatment of, 1982: July, 878–884

Dermatosis. See under specific disease, as Psoriasis.

Dermographism, 1982: July, 840 Desensitization. See Immunotherapy. Dexamethasone, for asthma, 1981: May, 602 Diabetes insipidus, 1981: March, 314–320

Diabetes insipidus, 1981: March, 314–320 Diabetes mellitus, atherosclerosis and, 1982: Nov., 1347–1348

causes of, 1982: Nov., 1209-1226 classification of, 1982: Nov., 1191-1197

Diabetes mellitus (Continued)

concomitant disease and, 1982: Nov.,

continuous insulin infusion in, 1982: Nov., 1269–1283

control of, during surgery, 1982: Nov., 1361-1372

with insulin, 1982: Nov., 1251-1267 diagnosis of, 1982: Nov., 1197-1205 gestational, 1982: Nov., 1194-1195, 1326-1329

glycosylated hemoglobin and, 1982: Nov., 1309–1315

hyperlipidemia with, 1982: Nov., 1347-1360

diet therapy for, 1982: March, 503-504 hyperosmolar nonketotic, 1983: Nov., 1198-1199

hypertension with, 1982: Nov., 1373–1388 in aged, 1983: March, 484–488

insulin requiring, multiple subcutaneous insulin injections in, 1982: Nov., 1251–1267

lactic acidosis and, 1983: July, 821 male sexual dysfunction in, 1982: Nov., 1389–1396

maturity onset of youth, 1982: Nov., 1197 meticulous control of, 1982: Nov.,

1317-1324

during pregnancy, 1982: Nov. 1329–1333

neuropathy of, 1981: Jan., 195 patient education in, 1982: Nov., 1293–1307

pregnancy and, management of, 1982: Nov., 1325-1346

prostaglandins and, 1981: July, 759–771 psychological aspects of, 1982: Nov., 1285–1292

self-monitoring of blood glucose in, 1982: Nov., 1227–1250

symposium on, 1982: Nov., 1191–1396 Diabetic gastroparesis, 1981: Nov., 1279 Diabetic ketoacidosis, 1981: Jan., 117–132,

1981: March, 326, 1983: July, 831–843; 1983: Nov., 1193–1198 Diabetic retinopathy, effect of pump therapy

on, 1982: Nov., 1279–1280 Diagnostic virology, 1983: Sept., 935–951

rapid. 1983: Sept., 953–972 Dialysis, bicarbonate-buffered, in lactic acidosis, 1983: July, 826–827

in acute tubular necrosis, 1981: Jan., 160 peritoneal, in psoriasis, 1982: May, 788 renal, pruritus in, 1982: Sept., 1127–1128

Diarrhea, 1981: March, 324 acute, altering intestinal microflora, 1982: May, 569–570

gastroenteritis and, 1983; Sept., 1032, 1036–1037

Diarrhea (Continued)

in aged, 1983: March, 338

infectious, 1982: May, 575-595; 1983: Jan., 203-220

in parasitic infections, 1983: Jan., 255–256 in terminally ill, 1982: Sept., 1175 in Yersinia enteritis, 1982: May, 639–653 nocturnal, 1981: Nov., 1372–1373

potassium depletion with, 1981: March, 384

secretory, assessment of dehydration, 1982: May, 613

fluid replacement, 1982: May, 613–616 noninfectious, 1982: May, 605–609 pathophysiology, 1982: May, 597–610 prophylaxis and therapy, 1982: May, 611–621

traveler's, prophylaxis, 1982: May, 618–619; 1983: Jan., 108, 213–219 with hypolipidemia, 1982: March, 479–480

Diazepam, in aged, pharmacokinetics of, 1982: Sept., 1023–1028

Dichloroacetate, in lactic acidosis, 1983: July, 826

Dichlorphenamide, 1981: March, 292 Dicloxacillin, 1983: Jan., 62–63

Dientamoeba fragilis infection(s), treatment, 1982: May, 713

Diethylcarbamazine, for parasitic infections, 1982: Jan., 250

Diet, yeast-free, urticaria and, 1982: July, 835–836

Diet therapy, for acne, 1982: July, 855–856 for familial hypercholesterolemia, 1982: March, 540

for hyperlipidemia, 1982: March, 485–518 Diffusion, respiratory, impaired, 1983: May, 558–559

Digitalis, in aged, 1983: March, 323–324 toxic effects, 1982: Sept., 1076–1077 in cor pulmonale, 1981: May, 512

 Diiodohydroxyquin, for intestinal protozoan infections, 1982: May, 715
 Diioxanide furoate, for intestinal protozoan

infections, 1982: May, 716 Diphtheria vaccine, 1983: Jan., 26–28 Diphyllobothriasis, 1982: May, 737

Disease, clinical signs of, in aged, 1983: March, 333–344

of skin, treatment of, 1982: July, **769–963.** See also under specific disease, as *Psoriasis*.

presenting as dementia, 1982: Sept., 1148 Disequilibrium syndrome, diabetic, 1981: Jan., 131

Disodium cromoglycate. See Cromolyn sodium.

Dissecting aneurysm, 1981: Jan., 94-102

Diuresis, forced, in drug elimination, 1983: Nov., 1284, 1289

osmotic, kaliuresis with, 1981: March, 381 solute, 1981: March, 306–310

water. 1981: March, 310-313

Diuretics, adverse drug interactions, 1981: March, 300

edema states and, 1981: March, 291–301 in cor pulmonale, 1981: May, 512 kaliuresis with, 1981: March, 381

overuse, hyponatremia from, 1981: March, 261

side effects of, 1981: March, 299 in diabetics, 1982: Nov., 1379–1381 sites of action, 1981: March, 292–297

Diuretic abuse, vs. Bartter's syndrome, 1983: July, 896–898

Diuretic therapy, as cause of alkalosis, 1983: July, 911

in metabolic alkalosis, 1983: July, 910 Diverticular disease of colon, in aged, 1983: March, 440–442

Diverticulum, bleeding from, 1983: Nov., 1226-1228

Dizziness, in aged, 1983: March, 353–354 DNA virus(es), oncogenic, 1983: Sept.,

1111–1121
"Dowager's hump," 1983: March, 522
Down's syndrome, immunodeficiency in,

1981: Sept., 971 Drug(s). See also specific agent. allergic reactions to, 1981: Sept.,

1089-1103 effects, sensitivity to, in aged, 1982: Sept., 1018-1021, 1075-1076

effects on high density lipoprotein levels, 1982: March, 417–418

elimination of, in overdose patient, 1983: Nov., 1283

for familial hypercholesterolemia, 1982; March, 540–546

for helminth infections, 1982: May, 721–742

for secretory diarrhea, 1982: May, 617–618

in etiology of lactic acidosis, 1983: July, 822–824

in etiology of renal tubular acidosis, 1983: July, 873

interactions, in aged, 1982: Sept., 1030–1031

intoxication, 1981: Jan., 28–31 nephrotoxic, in aged, 1983: March, 474–475

overdose, management of, 1983: Nov., 1279–1293

photosensitivity, 1982: July, 929–931 pulmonary reactions to, 1981: Sept., 1064 therapy. See also under specific agents or diseases. Drug(s), therapy (Continued)

antibiotic, in acute respiratory failure, 1983: May, 663

in aged, 1983: March, 285–287 antidiarrheal, 1983: Jan., 211–213 antihypertensive, in diabetics, 1982:

Nov., 1379-1387

antimicrobial, outpatient use, 1983: Jan., 3-16, 57-98. See also specific drug, as Penicillin.

side effects of, 1983: Jan., 113-129 antiviral, 1982: Sept., 1111-1113; 1983: Sept., 1163-1172

in chlamydial infections, 1983: Sept., 1069

in herpes infections, 1983: Sept., 1064, 1164–1167

in herpes simplex encephalitis, 1983: Sept., 1002–1005

in immunocompromised host, 1983. Sept., 1087–1088

in ocular infections, 1983: Sept., 973–974

in respiratory infections, 1983: Sept., 1021, 1167–1170

compliance with, in aged, 1982: Sept., 1077

for dementia, 1982: Sept., 1152–1155 for pain, 1982: Sept., 1053–1059, 1061–1071, 1091–1104, 1179–1182 for pruritus, 1982: Sept., 1119–1133

for psychiatric syndromes, in aged, 1983: March, 369–374

for symptom control, 1982: Sept., 971–1083. See also under specific drugs.

in acne, 1982: July, 859–866 in aged, 1982: Sept., 1073–1078. See also under specific agent, as Antipsychotic drug(s).

in asthma, 1983: May, 676–677, 680–681

in chronic urticaria, 1982: July, 838–839 in dermatomycoses, 1982: July, 887–893 in diabetics with hyperlipidemia, 1982: Nov., 1355–1356

in fungal infection, 1982: July, 875–876 in leukocytoclastic vasculitis, 1982: July, 946–947

in perioral dermatitis, 1982: July, 821–822

in pregnant asthmatics, 1983: May, 682 in relief of airway obstruction, 1983: May, 661–663

in respiratory muscle fatigue, 1983: May, 593

in terminally ill, 1982: Sept., 1174–1182 pharmacologic basis for, in aged, 1983: March, 315–331

Drug abuse, in aged, 1983: March, 352

Drug fever, 1983: Jan., 121

Dry mouth, in terminally ill, 1982; Sept., 1174

Dye(s), azo, urticaria and, 1982: July, 835Dysbetalipoproteinemia, familial, 1982:March, 441–452

Dysentery, amoebic, treatment, 1982: May, 708–709

bacillary, 1982: May, 623–638 in intestinal amoebiasis, 1982: May, 692–693

Dyskinesia, tardive, with neuroleptics, 1982: Sept., 1004

Dysmenorrhea, prostaglandins and, 1981: July, 930

Dysphagia, in aged, 1983: March, 349, 433-434

oropharyngeal, 1981: Nov., 1159–1167 Dyspnea, in aged, 1983: March, 337 in terminally ill, 1982: Sept., 1175 on exertion, 1981: May, 530

Dyspraxia, in aged, 1983: March, 349

EAR, infections, 1983; Jan., 164–166 Ectasia(s), vascular, bleeding from, 1983: Nov., 1226–1227

Eczema herpeticum, 1982: July, 810 Eczema seborrhoeicum, 1982: July, 826–829

Edema, cerebral, in overdose patient, 1983: Nov., 1282–1283

in aged, 1983: March, 338

noncardiac pulmonary, radiographic features of, 1983: Nov., 1311–1312

Edema states, diuretics and, 1981: March, 291–301

Education, patient, in diabetes, 1982: Nov., 1293–1307

Ejaculation, retrograde, in diabetics, 1982: Nov., 1389–1390

Elastase-antielastase hypothesis of emphysema, 1981: May, 652

Elastases, induction of emphysema with, 1981: May, 648–650

Elastin damage, in emphysema, 1981: May, 648

Elderly, anxiety in, 1982: Sept., 1014 arthritis in, 1982: Sept., 1047–1052 benzodiazepines in, 1982: Sept., 1017–1035

depression in, 1982: Sept., 1012–1014 drug therapy in, 1982: Sept., 1073–1078 health care of (symposium), 1983: March, 263–543. See also under specific

lower gastrointestinal bleeding in, 1983: Nov., 1226

narcotics in, 1982: Sept., 1079–1089 sleep disorders in, 1982: Sept., 971–991

Electrocardiography, in right ventricular enlargement, 1981: May, 499 Electroencephalography, in herpes simplex encephalitis, 1983: Sept., 996–997

Electrolyte(s). See also Acid-base balance; Fluids and electrolytes.

imbalance, in respiratory failure, 1983: May, **645–656**

loss, in ketoacidosis, 1983: July, 837 Electrolyte diuresis, 1981: March, 307

Electrolyte patterns, in metabolic acidosis, 1981: March, 322

Electrolyte regulation, prostaglandins and, 1981: July, 895

Embolectomy, pulmonary, 1983: Nov., 1188–1190

Embolism, pulmonary. See Pulmonary embolism.

Embolization, percutaneous transhepatic, for variceal bleeding, 1983: Nov., 1221

Emergency care, cardiac, 1981: Jan., 67–81 endocrine, 1983: Nov., 1193–1213

Emesis, in drug elimination, 1983: Nov., 1283

Emetine hydrochloride, for intestinal protozoan infections, 1982: May, 716

Emollients, bland, in psoriasis, 1982: July, 775–776

Emotional reactions, to acute illness, 1981: Jan., 3–14

Emphysema, 1981: May, 457 acute respiratory failure in, 1983: May,

657–668 airway responsiveness in, 1981: May, 476 left ventricular performance in, 1981:

May, 508–510 pathogenesis of, 1981: May, 647–656

right ventricular hemodynamics in, 1981: May, 501–505 Encephalitis, herpes simplex virus, 1983:

Sept., 991–1008 in immunocompromised host, 1983: Sept., 1083

Encephalopathy, hepatic, 1981: Jan., 209-226

hypoglycemic, with continuous subcutaneous delivery of insulin, 1982: Nov., 1399

toxic, 1981: Jan., 23, 28-31

Endocarditis, infectious, in aged, 1983: March, 282–284 prophylaxis, 1983: Jan., 106–108

rifampin for, 1982: Jan., 160 Endocrine disorders, autoimmune, diabetes and, 1982: Nov., 1215–1217

critical, 1983: Nov., 1193-1213 in aged, 1983: March, 481-495

Endophthalmitis, bacterial, 1983: Jan., 149 Endoscopy, in gastrointestinal bleeding,

1983: Nov., 1225–1226 Endotracheal intubation. See under Intubation.

Energy requirements, of critically ill, 1983: Nov., 1298–1299 Entamoeba histolytica infection(s), 1982: May, 689-705

Entamoeba polecki infection(s), treatment, 1982: May, 714

Enteral alimentation, in critically ill, 1983: Nov., 1299–1300

Enteric infection(s), 1983: Jan., 203–220, 249

in homosexual men, 1983: Jan., 236–238 Enteritis, fungal, 1982: May, 675–687 Yersinia, 1982: May, 639–653

Enterobiasis, 1982: May, 729-731

Enterogastric reflux, 1981: Nov., 1278–1279 Enterovirus infection(s), gastroenteric, 1983: Sept., 1047

in immunocompromised host, 1983: Sept., 1081

Enzyme immunoassay(s), in virus detection, 1983: Sept., 958–961

Eosinophil chemotactic factor of anaphylaxis (ECF-A), 1981: Sept., 951

Eosinophil(s), in asthma, 1981: Sept., 1018 in immediate hypersensitivity reactions, 1981: Sept., 951

in immunologic lung disease, 1981: Sept., 1055–1071

Eosinophilia, in parasitic infections, 1983: Jan., 255–257

in pulmonary disease, 1981: Sept., 1055–1071

Eosinophilic pneumonia, 1981: Sept., 1063–1064, 1096

Ephedrine, 1981: May, 586 Epiglottitis, 1983: Jan., 166-168

Epinephrine, in obstructive lung diseases, 1981: May, 580

Epstein-Barr virus, oncogenicity of, 1983: Sept., 1115–1117 serodiagnostic criteria for, 1983: Sept.,

946–947
Epstein-Barr virus infection(s), in homosex-

ual men, 1983: Sept., 1100–1101 in immunocompromised host, 1983: Sept., 1081–1082

Equipment, failure, of insulin infusion devices, 1982: Nov., 1281

for continuous delivery of insulin, 1982: Nov., 1272–1274

for self-monitoring of blood glucose, 1982: Nov., 1230–1232

Erythema multiforme, 1981: Jan., 235 Erythromycin, 1982: Jan., 79–89; 1983: Jan..

resistance to, 1982: Jan., 34

Escherichia coli, heat-labile vs. heat-stable, 1982: May, 603–604

in pathogenesis of secretory diarrhea, 1982: May, 597–599, 602–605, 612–613 Esophageal disease, surgery in, 1981: Nov.,

1235–1268 Esophageal diverticula, 1981: Nov., 1252–1258 Esophageal motility, disorders, surgical management, 1981: Nov., 1235–1268 gastrointestinal hormones and, 1981:

Nov., 1112–1115 prostaglandins and, 1981: July, 774 radiographic evaluation, 1981: Nov.,

1173–1194 Esophageal scintigraphy, 1981: Nov., 1293–1297

Esophageal spasm, diffuse, 1981: Nov., 1247–1250

behavioral therapy for, 1981: Nov., 1401

Esophageal varices, bleeding, 1983: Nov., 1219–1222

Esophagus, cancer of, in aged, 1983: March, 440

disorders, chest pain from, 1981: Jan., 61 in aged, 1983: March, 433-434

Estriol, measurement of, in diabetic pregnancy, 1982: Nov., 1337–1341

Estrogen therapy, in acne, 1982: July, 861–862

in osteoporosis, 1983: Mar., 489–490 Ethacrynic acid, 1981: March, 293 Ethambutol, 1982: Jan., 210–217; 1983:

Jan., 82–83 Ethanol, lactic acidosis and, 1983: July, 823–824

Ethylenediamine hydrochloride, dermatitis from, 1981: Sept., 1084

Ethylene glycol, intoxication, 1981: March, 328

lactic acidosis and, 1983: July, 824 Exercise, effect on high density lipoprotein levels, 1982: March, 411–412

hypoglycemia and, 1982: Nov., 1246, 1262 in chronic obstructive lung disease, 1981: May, 525–547, 640

Exfoliation, in acne, 1982: July, 859

Exfoliative dermatitis, 1981: Sept., 1098 Extracellular fluid, buffering mechanisms of, 1983: July, 775–776

Extracellular fluid volume, maldistribution of, 1981: March, 291

sodium concentration and, 1981: March, 259

Eye, infections of, 1983: Jan., 131-152
 viral infections of, 1983: Sept., 973-990
 Eyelids, infections of, 1983: Jan., 133-139

FACE, fungal infection, 1982: July, 880
Fall(s), in aged, benzodiazepines and, 1982:
Sept., 1021

Familial dysbetalipoproteinemia, 1982: March, 441–452

Familial hypercholesterolemia. See Hypercholesterolemia, familial.

Family studies, of diabetes, 1982: Nov., 1210-1212, 1220-1222

Fanconi's syndrome, renal tubular acidosis and, 1983: July, 873

Fat, dietary, effect on lipid metabolism, 1982: March, 491–495

Fecal impaction, treatment for, 1982: Sept., 1139-1140

Fecal incontinence, behavioral therapy, 1981: Nov., 1405–1408 treatment for, 1982: Sept., 1135–1139

Fenamate(s), for pain, 1982: Sept., 1057–1058

Fenoprofen, as prostaglandin synthesis inhibitor, 1981: July, 741, 749

for pain, 1982: Sept., 1057 Fenoterol, 1981: May, 585

Fetus, heart rate monitoring in, 1982: Nov., 1337–1338

lung maturity, maternal diabetes and, 1982: Nov., 1335–1337

risk, maternal diabetes and, 1982: Nov., 1325–1346

Fever, allergic, 1981: Sept., 1095 drug-induced, 1983: Jan., 121 in aged, 1983: March, 335–336 in parasitic infections, 1983: Jan., 254–255 pharyngoconjunctival, 1983: Sept.,

986–987 Fiber, dietary, effect on lipid metabolism, 1982: March, 497

for constipation, 1982: Sept., 1138–1139 Fibrin degradation products, in septic lung

injury, 1983: May, 707–708
Fibrosis, pulmonary, in acute respiratory failure, 1983: May, 728

"Fish eye" disease, 1982: March, 478–479 Flucocystine, for systemic mycoses, 1982: Jan., 227–228

Flucytosine, 1983: Jan., 78

Fluid, extracellular, buffering in, 1983: July, 775–776

Fluid balance, in respiratory failure, 1983: May, 645–656

Fluids and electrolytes, in acute tubular necrosis, 1981: Jan., 159

in critically ill, 1983: Nov., 1302

in diabetic ketoacidosis, 1983: Nov., 1194–1195 in renal failure, 1983: Nov., 1338–1339

regulation, prostaglandins and, 1981: July, 895–897 Fluid therapy, in ketoacidosis, 1983: July,

839 monitoring of, in critically ill, 1983: Nov., 1348

5-Fluorocytosine, in fungal infection, 1982: July, 887–888

Flurazepam, for insomnia, 1982: Sept., 976 Flushing, in etiology of rosacea, 1982: July, 823–824

Folate, deficiency, in aged, 1983: March, 305–306

Fomite(s), in transmission of scabies, 1982: July, 959–960

Foot, fungal infection, 1982: July, 878–880 Fructose-1,6-diphosphatase deficiency, lactic acidosis and, 1983: July, 824

Fungal enteritis, 1982: May, 675–687 in immunocompromised patient, 1982: May, 748

Fungal infection(s), cutaneous, treatment of, 1982: July, 873–893

in terminally ill, 1982: Sept., 1176–1177 pneumonia and, 1983: Nov., 1235, 1238–1239

Fungal respiratory infection(s), outpatient therapy, 1983: Jan., 182–183

Furadantin. See Nitrofurantoin.
Furazolidone, for intestinal protozoan infections, 1982: May, 716

Furosemide, 1981: March, 293, 422 Furunculosis, rifampin for, 1982: Jan., 161

Gas(ES), blood. See *Blood gases*. Gas exchange, abnormal, 1983: May, 557-571

in mechanical ventilation, 1983: May, 625-626

Gastric. See also Stomach.

Gastric-cholecystic imaging, 1981: Nov., 1301–1308

Gastric lavage, in drug elimination, 1983: Nov., 1283

Gastric secretion, prostaglandins and, 1981: July, 776–778

Gastritis, gastrointestinal bleeding and, 1983: Nov., 1222–1225

Gastroenteritis, Vibrio, 1982: May, 665–673 viral, 1982: May, 575–595; 1983: Sept., 1031–1058

in aged, 1983: March, 289 Gastroesophageal reflux, 1981: Nov.,

1195–1222, 1223–1234 hehavioral therapy, 1981: Nov., 1401 specific therapy, 1981: Nov., 1225–1231

Gastroesophageal scintigraphy, 1981: Nov., 1297–1301

Gastrointestinal bleeding, 1983: Nov., 1215–1231

in acute respiratory failure, 1981: May, 573

liver disease and, 1981: Jan., 218 of lower tract, 1983: Nov., 1225–1228

Gastrointestinal complications, in acute respiratory failure, 1983: May, 695, 729–734
 Gastrointestinal hormones. See under Hor-

mone(s), and specific names.
Gastrointestinal reactions, to antibiotics,
1983: Jan., 123–124

Gastrointestinal symptom(s), in terminally ill, 1982: Sept., 1174

Gastrointestinal tract, disorders, effect on aging lung, 1983: March. 425 in aged, 1983: March. 433-444 in respiratory alkalosis, 1983: July, 919 infections, 1983: Jan., 203-220 inflammatory disease of. See Inflamma-

tory bowel disease. motility disorders of (symposium), 1981: Nov., 1109–1141

behavioral approaches to, 1981: Nov., 1397–1411

neural regulation of motility, 1981: Nov., 1129-1147

sleep physiology and, 1981: Nov., 1359–1376

Gaviscon, for gastroesophageal reflux, 1981: Nov., 1227–1228

Genetic aspects, of diabetes, 1982: Nov., 1210–1212, 1220–1222

Genital herpes infections, in men, 1983: Jan., 243–244

in women, 1983: Jan., 226–228 Genital infection(s), viral, 1983: Sept., 1059–1073

in homosexual men, 1983: Sept., 1097–1098

Genital ulcers, 1983: Jan., 242–246 Genital warts, 1983: Jan., 246; 1983: Sept.,

1064–1065 Genitourinary tract, disorders, in aged,

1983: March, 445–461
Geriatric medicine, clinical (symposium),

1983: March, 263–543
Gestational diabetes, 1982: Nov.,

1194–1195, 1326–1329 Giardiasis, in immunocompromised patient,

1982: May, 749 metronidazole for, 1982: Jan., 124

treatment, 1982: May, 712–713 Gilles de la Tourette's syndrome, neuroleptics for, 1982: Sept., 1005

Gland(s). See under specific type, as Pituitary.

Glomerular function, acute tubular necrosis and, 1981: Jan., 152 indices of, 1983: Nov., 1326

Glomerulonephritis, acute, 1981: March, 416 in aged, 1983: March, 470–472

renal failure and, 1983: Nov., 1327–1328 Glucagon secretjon, in diabetes mellitus,

Glucagon secretion, in diabetes mellitus, 1982: Nov., 1317–1319 prostaglandins and, 1981: July, 764

prostaglandins and, 1991: July, 764 Glucocorticoid(s). See also Corticosteroid(s). deficiency of, hypomineralocorticoidism and, 1983: July, 882 excess of, 1983: July, 894

Glucocorticoid insufficiency, chronic hyponatremia with, 1981: March, 266

Glucose. See also Blood glucose. diuresis, 1981: March, 308 Glucose (Continued)

homeostasis, prostaglandins and, 1981: July, 759–771

hyperkalemia and, 1981: March, 375 serum, hypertonic syndromes and, 1981: March, 281–284

tolerance, 1981: July, 765

Glucose-6-phosphate dehydrogenase deficiency, lactic acidosis and, 1983: July, 824

Glucose tolerance test, oral, 1982: Nov., 1200–1204

Glycoslyated hemoglobin, in diabetes mellitus, 1982: Nov., 1309–1315

levels, effect of pump therapy on, 1982: Nov., 1278 in diagnosis of diabetes, 1982: Nov.,

1204 Goeckerman's regimen, in psoriasis, 1982:

July, 782 Goiter, nodular, in aged, 1983: March,

508–510 Gonad(s), disorders, in aged, 1983: March,

488–492 Congress 1982, July 915, 917, 1982, Jon

Gonorrhea, 1982: July, 915-917; 1983: Jan., 240-242, 248

Gout, 1981: March, 404 acute, 1981: Jan., 179

Granulocytopenia, as drug reaction, 1981: Sept., 1098

Granuloma inguinale, 1982: July, 921–922 Granuloma, trichophytic, 1982: July, 880–881

Granulomatosis, allergic, 1982: July, 949–951

Wegener's, 1982: July, 948-949 Granulomatous disease, chronic, 1981: Sept., 968

Gray syndrome, due to chloramphenicol, 1982: Jan., 97–98

Griseofulvin, 1983: Jan., 78–79
in fungal infections, 1982: July, 888–889
Guillain-Barré syndrome, 1981: Jan., 194

HDL. See High density lipoproteins (HDL). Health, models, in patient education, 1982: Nov., 1293-1307

Heart. See also Cardiac.

arrhythmias. See Arrhythmia(s). chest pain and, 1981: Jan., 53–59

disease, effect on aging lung, 1983: March, 426-427

in aged, 1983: March, 379–394 pulmonary. See *Cor pulmonale*.

failure, chronic obstructive lung disease and, radiographic features of, 1983: Nov., 1314–1315 congestive in aged, 1983; March

congestive, in aged, 1983: March, 391-392

Heart, failure, congestive (Continued) radiographic features of, 1983: Nov., 1312–1315

vs. chronic obstructive lung disease, 1981: May, 535

infarct. See Myocardial infarction. infections, cephalosporins for, 1982: Jan., 184–186

valves, degenerative calcification of, 1983: March, 392–393

Heartburn. See Gastroesophageal reflux.
Helminth infections, drug therapy for, 1982:
May, 721–742

Hematologic complications, of acute respiratory failure, 1983: May, 738–739

Hematologic disorders. See specific disorders.

Hematologic reactions, to drugs, 1981: Sept., 1097; 1983: Jan., 121–123

Hemodynamic monitoring, of critically ill, 1983: Nov., 1343–1360

Swan-Ganz catheter, 1981: Jan., 69–73 Hemoglobin A_k. See Glycosylated hemoglobin.

Hemolytic anemia, drug-induced, 1981: Sept., 1097

Hemoperfusion, in drug elimination, 1983: Nov., 1284

Hemophilus influenzae pneumonia, 1983: Nov., 1234–1235

Hemorrhage, diverticular, in aged, 1983: March, 441–442

evaluation and management of, 1981: Jan., 133–146

gastrointestinal, 1983: Nov., 1215–1231 in acute respiratory failure, 1983: May, 729–733

liver disease and, 1981: Jan., 218 lower gastrointestinal, 1983: Nov., 1225–1228

thrombolytic therapy and, 1983: Nov., 1186–1187

Hemostasis, 1981: Jan., 133

Henderson-Hasselbalch equation, 1983: May, 647, 653

in metabolic alkalosis, 1983: July, 809 pH and, 1983: July, 799

Henle's loop, bicarbonate reabsorption and, 1983: July, 755

Heparin, low-dose, in prevention of thromboemboli, 1983: May, 726–727; 1983: Nov., 1180–1181

Hepatic. See also Liver.

Hepatic disorders, in aged, 1983: March, 436

Hepatic encephalopathy, 1981: Jan., 209-226

Hepatic reactions to drugs, 1981: Sept., 1096 Hepatitis, in homosexual men, 1983: Jan., 238; 1983: Sept., 1094–1097 interferon for, 1983: Sept., 1155

Hepatitis B vaccine, 1983: Jan., 33–34; 1983: Sept., 1132–1137

Hepatitis B virus, oncogenicity of, 1983: Sept., 1119–1121

Heroin, for pain, 1982: Sept., 1062, 1093Herpes genitalis, in men, 1983: Jan., 243–244

in women, 1983: Jan., 226-228 Herpes simplex virus, detection of in cell

culture, 1983: Sept., 948–949 oncogenicity of, 1983: Sept., 1112–1115 Herpes simplex virus encephalitis, 1982:

Sept., 991-1008

Herpes simplex infection(s), 1982: July, 807–810

drugs for, 1983: Sept., 1164–1167 genital, 1983: Sept., 1059–1064 in homosexual men, 1983: Sept., 1097–1098

in immuno compromised host, 1983: Sept., 1082-1083

ocular, 1983: Sept., 974-982

Herpes simplex virus vaccine, 1983: Sept., 1141–1143

Herpes zoster ophthalmicus, 1983: Sept., 982–985

Herpes zoster virus infection(s), 1982: July, 810–812

in aged, 1983: March, 288, 533–534
in immunocompromised host, 1983: Sept., 1083–1084

prevention, 1982: Sept., 1109–1110 therapy, 1982: Sept., 1105–1118

Herpetic esophagitis, in immunocompromised patient, 1982: May, 748
 Hetacillin, 1983: Jan., 63

Hiccough, in terminally ill, 1982: Sept., 1175High density lipoproteins (HDL), atherosclerosis and, 1982: March, 331, 390

characterization, 1982: March, 403–404 clinical significance, 1982: March, 431–440 deficiency, with planar xanthomatosis, 1982: March, 479

diet-induced changes in, 1982: March, 380–384

levels, effect of alcohol, 1982: March, 414 effect of constitutional factors, 1982: March, 406–409

effect of dietary lipids and carbohydrates, 1982: March, 412–414

effect of energy balance and nutrition, 1982: March, 409–410

effect of obesity, 1982: March, 409–410 effect of physical activity, 1982: March, 411–412

pathologic states affecting, 1982: March, 415–416 High density lipoproteins, levels (Continued) pharmacologic effects on, 1982: March, 417–418

measurement, 1982: March, 434–436 in clinical practice, 1982: March, 437–438

regulation, 1982: March, 403–430 metabolism, 1982: March, 404–406 relation to very low density lipoproteins, 1982: March, 521–522

subclasses, 1982: March, 378–380, 433–434

with apo-E (HDL_c), origin, 1982: March, 384–387

role in cholesterol metabolism, 1982: March, 387–390

High-frequency ventilation, 1983: May, 633–643

Hirschsprung's disease, 1981: Nov., 1380–1382

Histamine, in immediate hypersensitivity reactions, 1981: Sept., 951

Histamine releasing agents, urticaria and, 1982: July, 834 Histoplasmosis, 1982: May, 678–680

Histoplasmosis, 1982: May, 678–680 Hives. See *Urticaria*.

HLA antigens, diabetes and, 1982: Nov., 1195–1196, 1210–1212

diabetic complications and, 1982: Nov., 1217-1218

prostaglandins and, 1981: July, 833 RNA viruses and, 1983: Sept., 1111

Homeostasis, mechanisms of, 1981: March, 284–286

Homosexual men, venereal disease in, 1983: Jan., 236–240; 1983: Sept., 1093–1104

Honeymoon state, of insulin therapy, 1982: Nov., 1239

Hookworm infection, 1982: May, 731–742 Hordeolum, 1983: Jan., 135

Hormonal therapy, for central diabetes insipidus, 1981: March, 316

Hormone(s). See also specific hormones. adrenocortical. See Corticosteroid(s). age-related changes, 1983: March, 481–495

gastrointestinal, migrating motor complex and, 1981: Nov., 1318–1319 motility and, 1981: Nov., 1111–1127 sex. See Estrogen.

thyroid. See *Thyroid hormones* and specific hormones.

vasoactive, prostaglandin production and, 1981: July, 881–889

Hospice, for terminal care, 1982: Sept., 1161-1168

Hospital(s), control of antibiotic-resistant bacteria in, 1982: Jan., 34–35

Hospital-acquired infection(s). See Nosocomial infection(s). Host, defense, in cancer, prostaglandins and, 1981: July, 829-844

factors, in obstructive pulmonary diseases, 1981: May, 455–456

Human papilloma virus infection(s), 1982: July, 812–814

Humidification, in high-frequency ventilation, 1983: May, 637

in mechanical ventilation, 1983: May, 601–613

Humoral immunity, assessment of, 1981: Sept., 974

Humoral mediator(s), of septic lung injury, 1983: May, 703–708

Huntington's disease, in aged, 1983: March, 356

neuroleptics for, 1982: Sept., 1005 Hydrochloric acid, in metabolic alkalosis, 1983: May, 653, 654

1983: May, 653-654 Hydrochlorothiazide, 1981: March, 294, 317 Hydrogen ion, secretion, aldosterone and,

1983: July, 880–881 in urinary acidification, 1983: July, 753–768

Hydromorphone, for pain, 1982: Sept., 1063, 1093

11- β -Hydroxylase deficiency, 1983: July. 893 17- α -Hydroxylase deficiency, 1983: July, 893 Hydroxystilbamidine isethionate, for sys-

temic mycoses, 1982: Jan., 222 Hydroxyurea, in psoriasis, 1982: July, 787 Hymenolipiasis, 1982: May, 739

Hymenoptera venom, in immunotherapy, 1981: Sept., 996, 1002

Hyperaldosteronism, 1983: July, 890–898 alkalosis and, 1983: July, 912 secondary, 1983: July, 895–898

Hyperalimentation, parenteral, lactic acidosis and, 1983: July, 823

Hyperbicarbonatemia, 1981: March, 333 Hypercalcemia, 1981: March, 386–389 of cancer, prostaglandins and, 1981: July, 845–853

Hypercalcemic crisis, 1983: Nov., 1206–1209 Hypercalciuria, renal tubular acidosis and, 1983: July, 872–873

Hypercapnia, 1983: July, 917. See also Acidosis, respiratory.
 alkalosis and, 1983: July, 911–912

chronic, 1983: May, 648–649 Hypercholesterolemia, abnormalities of cho-

lesterol transport in, 1982: March, 371 differential diagnosis, 1982: March, 539–540

familial, cholesterol synthetic rates, 1982: March, 354–355

diet therapy for, 1982: March, 540 drug therapy for, 1982: March, 540-546 homozygous, 1982: March, 336-338 Hypercholesterolemia, familial, homozygotes with (Continued)

mechanisms for high plasma LDL levels, 1982: March, 346–351 therapy, 1982: March, 358, 546

low density lipoprotein receptor defect in, 1982: March, 335–362

pathogenesis at cellular level, 1982: March, 338–341

pathogenesis at whole body level, 1982: March, 341–343

surgery for, 1982: March, 546 treatment, 1982: March, 355–358, 537–550

in diabetics, 1982: Nov., 1348–1351 Hypercortisolism. See *Cushing's disease*. Hypereosinophilic syndrome, 1981: Sept., 1066

Hyperglycemia. See also Diabetes mellitus. consequences of, 1982: Nov., 1319–1320 hypertonic syndromes and, 1981: March, 281–284

Hyperkalemia, 1981: March. 374–379; 1983: July, 803

emergency treatment of, 1981: Jan., 165–176

hyperchloremic metabolic acidosis and, 1983: July, 789–790

hypoaldosteronism and, 1983: July, 881-890

in hypertensive diabetics, 1982: Nov., 1378 in renal failure, 1983: Nov., 1337–1338 in renal tubular acidosis, 1983: July, 874–876

in renal tubular necrosis, 1981: March, 424 Hyperkeratosis, subungual, in psoriasis, 1982: July, 773

Hyperlactacidemia, 1983: July, 815–829 Hyperlipidemia(s), approach to patient,

1982: March, 319-333 athersclerosis in, 1982: March, 331 diet therepy for, 1983: March, 485, 51

diet therapy for, 1982: March, 485–518 familial dysbetalipoproteinemia and, 1982: March, 448–450

hypertension with, salt restriction for, 1982: March, 513–515

in children, diet therapy for, 1982: March, 504

of pregnancy, diet therapy for, 1982: March, 504–505

single diet concept for, 1982: March, 499-502

therapeutic decision-making, 1982: March, 331–332

with diabetes, 1982: Nov., 1347–1360 diet therapy for, 1982: March, 503–504 xanthomas in, 1982: March, 330–331

Hyperlipoproteinemia, atherogenic, 1982: March, 375–402 with diabetes, 1982: Nov., 1348–1351 Hypermineralcorticoidism, in metabolic alkalosis, 1983: July, 907–908

Hypernatremia, hypertonic syndromes and, 1981: March, 271–281

Hyperosmolality, 1981: March, 272 in ketoacidosis, 1983: July, 837

Hyperosmolar nonketotic coma, 1983: Nov., 1198–1199

Hyperparathyroidism, 1981: March, 387 Hyperphosphatemia, 1981: March, 391, 396–398

in chronic renal failure, 1981: March, 442 Hyperplasia, nodular lymphoid, 1982: May, 745

Hypersensitivity, arachidonic acid metabolites as mediators of, 1981: July, 809-828

immediate, in..nune mechanisms in, 1981: Sept., 941–957

mediators of, 1981: Sept., 951-955 Hypersensitivity reactions, to penicillin,

1983: Jan., 114–121 Hypertension, hyperlipidemia with, salt restriction for, 1982: March, 513–515 in aged, 1983: March, 395–417 in diabetics, 1982: Nov., 1373–1388 prostaglandins and 1981: July 906

prostaglandins and, 1981: July, 906 pulmonary artery, in obstructive lung disease, 1981: May, 489–495, 554 systolic, in diabetics, 1982: Nov.,

1378–1379

Hyperthermia, in overdose patient, 1983:

Nov., 1282–1283 Hyperthyroid crisis, *1983*: Nov., 1202–1203 Hyperthyroidism, in aged, *1983*: March, 499–503

myopathy of, 1981: Jan., 197

Hypertonicity, hypernatremia and, 1981: March, 271–281 potassium balance and, 1981: March, 365

treatment of, 1981: March, 286–288

Avpertriglyceridemia, 1982: March, 519–53

Hypertriglyceridemia, 1982: March, 519–535
 in diabetics, 1982: Nov., 1348–1351
 mechanisms, 1982: March, 522–527
 Hyperuricemia, 1981: March, 299, 403–409

Hypoadrenocorticism, 1983: Nov., 1205–1206

Hypoaldosteronism, 1981: March, 376, 378, 434; 1983: July, 881–890

Hypoalphalipoproteinemia, familial, 1982: March, 478

Hypobetalipoproteinemia, familial, 1982: March, 472–473

with chylomicronemia, 1982: March, 474

Hypocalcemia, 1981: March, 389–392
 Hypocalcemic crisis, 1983: Nov., 1209–1210
 Hypocapnia, 1983: July, 916. See also Alkalosis, respiratoru.

chronic, 1983: May, 648-649

Hypochlorhydria, bacterial overgrowth and, 1982: May, 563

Hypocortisolism, 1983: Nov., 1205–1206Hypogammaglobulinemia, common variable acquired, 1982: May, 745

X-linked infantile congenital, 1982: May,

Hypoglycemia, exercise-induced, 1982: Nov., 1246

in aged, 1983: March, 486–487 prevention of, 1982: Nov., 1261–1262 with continuous delivery of insulin, 1982:

Nov., 1280-1281

Hypoglycemic agents. See Insulin. Hypoglycemic coma, 1983: Nov., 1199–1202 Hypokalemia, 1981: Jan., 199; 1983: July,

hyperaldosteronism and, 1983: July, 890–898

in metabolic alkalosis, 1983: July, 906 in renal tubular acidosis, 1983: July, 864

Hypolipidemia(s), 1982: March, 469–484 diarrhea with, 1982: March, 479–480 immunoglobulin disorders with, 1982: March, 480

liver disease with, 1982: March, 480 malnutrition with, 1982: March, 479–480

Hypomagnesemia, in Bartter's syndrome, 1983: July, 896

Hypomineralocorticoidism, 1983: July, 881–890

Hyponatremia, 1981: March, 251–269
 chronic, 1981: March, 263–267
 hypotonic, 1981: March, 267

Hypophosphatemia, 1981: March, 393–396 Hypophysis. See *Pituitary gland*. Hyposensitization. See *Immunotherapy*.

Hypotension, in acute respiratory failure, 1983: May, 735

orthostatic, in aged, 1983: March, 386–387, 404

in diabetics, 1982: Nov., 1379 with tricyclic antidepressants, 1982: Sept., 1041–1042

Hypothermia, in aged, 1983: March, 336 Hypothyroid crisis, 1983: Nov., 1203–1205 Hypothyroidism, hyponatremia with, 1981:

March, 267 in aged, 1983: March, 503-508

Hypotonic hyponatremia, 1981: March, 267 Hypouricemia, 1981: March, 409

Hypoventilation, alveolar, 1983: May, 558 Hypoxemia, acute, in respiratory failure, 1983: May, 555

of chronic obstructive lung disease, home oxygen therapy for, 1981: May, 615–627 treatment, in acute respiratory failure, 1981: May, 567–569

Hypoxia, tissue, lactic acidosis and, 1983: July, 820–821 IATROGENIC disease, cutaneous, 1981: Sept., 1083–1088

Ibuprofen, as prostaglandin synthesis inhibitor, 1981: July, 741, 748–749 for pain, 1982: Sept., 1056–1057

Idiopathic diabetes, 1982: Nov., 1192–1194. See also Diabetes mellitus.

Idoxuridine, 1983: Sept., 973–974, 1164 for viral infections, 1982: Jan., 241

IgA. See Immunoglobulin A. IgE. See Immunoglobulin E.

IgM. See Immunoglobin M.

Ileitis, acute terminal, 1982: May, 643–644Ileum. ulcerations, due to Yersinia infection, 1982: May, 644

Imidazoles, for systemic mycoses, 1982: Jan., 228–230

Imidazolidinyl urea, dermatitis from, 1981: Sept., 1085

Imipramine, for cataplexy, 1982: Sept., 980 for depression, 1982: Sept., 1037–1045 for sleepwalking, 1982: Sept., 984

Immune complex reactions, 1981: Sept., 943

Immune response, cell-mediated, in aged, 1983: March, 268–270 humoral, in aged, 1983: March, 264–268

normal, 1981: Sept., 959–960 Immune serum globulins, human, 1983:

Jan., 34 Immune system, age-related changes, 1983: March, 263–272

Immune system, deficiency. See Immunodeficiency.

in immediate hypersensitivity, 1981: Sept., 941-957

effect of interferon on, 1983: Sept., 1148-1149

in obstructive airway disease, 1981: May, 683–685

viruses and, 1983: Sept., 1076–1079 Immunity, humoral, defects in, 1981: Sept., 961

normal, 1981: Sept., 959

to viruses, 1983: Sept., 1038–1041, 1045–1046, 1077

determination of, 1983: Sept., 965–966 Immunization, against infectious disease, 1983: Jan., 17–38

Immunodeficiency, 1981: Sept., 959–976. See also Immune system.

herpes zoster and, 1982: Sept., 1106 laboratory evaluation for, 1981: Sept.,

973–974 primary, 1981: Sept., 961–970

secondary, 1981: Sept., 970 syndromes, gastrointestinal infections and, 1982: May, 743–753

viral infections and, 1983: Sept., 1075–1092, 1098–1100 Immunofluorescence, in virus detection, 1983: Sept., 956–958

Immunoglobulin(s), alterations, in obstructive lung disease, 1981: May, 683–685 disorders, with hypolipidemia, 1982:

March, 480 in lung secretions of smokers, 1981: May,

Immunoglobulin A, deficiency, 1982: May, 745–746

selective, 1981: Sept., 965

Immunoglobin E, in allergic rhinitis, 1981: Sept., 978

in immediate hypersensitivity reactions, 1981: Sept., 945–950

in obstructive lung diseases, 1951: May, 455 Immunoglobulin M, antibody assays, in diagnostic virology, 1983: Sept., 945–946, 963–965

Immunologic disorders, pulmonary, eosinophils and, 1981: Sept., 1055-1071

Immunologic methods, in virus detection, 1983: Sept., 955–962

Immunology, of normal gut, 1982: May, 743-744

Immunostimulation, by prostaglandin synthetase inhibitors, 1981: July, 830–832

Immunosuppressive therapy, pneumonia and, 1983: Nov., 1243-1247

Immunotherapy, in allergic rhinitis, 1981: Sept., 983, 988–990

in asthma, 1981: Sept., 1040

in atopic disorders, 1981: Sept., 987–1012 adverse reactions to, 1981: Sept., 1002 selecting patients for, 1981: Sept., 998–1000

Impetigo, of eyelids, 1983: Jan., 136
Impotence, in aged, 1983: March, 454–457
organic erectile, in male diabetics, 1982:
Nov., 1390–1394

Incontinence, fecal, behavior therapy, 1981: Nov., 1405–1408

in aged, 1983: March, 338–339, 436, 449–452

in terminally ill, 1982: Sept., 1176 Indanyl carbenicillin, 1983: Jan., 65–66 Inderal. See *Propranolol*.

Indomethacin, as prostaglandin synthesis inhibitor, 1981: July, 730–735 for pain, 1982: Sept., 1055–1056

Infant(s), gastrointestinal bleeding in, 1983: Nov., 1228

viral gastroenteritis in, 1983: Sept., 1036–1037

Infarction, cerebral. See Transient ischemic attack(s).

pituitary, 1981: Jan., 105–116 Infection(s). See also Sepsis.

acute respiratory failure with, 1981: May, 571

Infection(s) (Continued)

catheter-associated, 1983: Jan., 198–199 fungal, treatment of, 1982: July, 873–893 gastrointestinal, 1983: Jan., 203–220 immunodeficiency and, 1981: Sept., 971 in respiratory failure, 1983: May, 701–715 mixed, combination therapy for, 1982: Jan., 17–18

nosocomial, 1983: Nov., 1251–1277. See also under Nosocomial infection(s). in acute respiratory failure, 1983: May,

obstructive lung disease and, 1981: May, 684

ocular, 1983: Jan., 131-152

of lower respiratory tract, 1983: Jan., 173–186

of upper respiratory tract, 1983: Jan., 153–171

of urinary tract, 1983: Jan., 187–201 parasitic, diagnosis of, 1983: Jan., 253–258 pulmonary. See *Lung(s)*, infections and specific pathogens.

respiratory, airway reactivity and, 1981: Sept., 1045–1053

sexually transmitted, in men, 1983: Jan., 235–251

in women, 1983: Jan., 221-234 treatment of, 1982: July, 915-925

susceptibility to, nutritional status and, 1983: Nov., 1295–1296

urinary tract, in aged, 1983: March, 452–453

viral, diabetes and, 1982: Nov., 1213-1214 of skin, 1982: July, 807-817

symposium on, 1983: Sept., 935–1172. See also Virus(es); Viral infections.

Infectious diseases, immunization against, 1983: Jan., 17–38

in aged, 1983: March, 273-293 in office practice, symposium on, 1983:

Jan., 3–258. See also specific infections, as *Blepharitis*.

outpatient therapy of, 1983: Jan., 3–16 Infestation, microfilarial, 1981: Sept., 1066 Inflammation, arachidonic acid metabolites as mediators of, 1981: July, 809–828

Inflammatory bowel disease, in aged, 1983: March, 442–443

prostaglandins and, 1981: July, 781–782 Influenza vaccine, 1983: Jan., 30–31; 1983: Sept., 1020

Influenza virus infection(s), 1983: Sept., 1012, 1016–1017

drugs for, 1983: Sept., 1167–1169 in aged, 1983: March, 287–288, 427–428 nosocomial, 1983: Sept., 1019

prophylaxis, 1983: Jan., 103-104

Influenza virus pneumonia, 1983: Nov., 1235

Insect stings, anaphylactic reaction to, 1981: Jan., 229

Insomnia, 1982: Sept., 972–977 in terminally ill, 1982: Sept., 1177 treatment for, 1982: Sept., 974–977

Insulin, adjustments in dose, 1982: Nov., 1240–1244, 1258–1260

continuous subcutaneous infusion, 1982: Nov., 1254–1257

by pump, 1982: Nov., 1237–1238, 1269–1283

psychological reactions to, 1982: Nov., 1285–1292

during pregnancy, 1982: Nov., 1331 deficiency, in diabetes, 1982: Nov., 1251 delivery, advances in, 1982: Nov., 1320 management, during surgery, 1982: Nov., 1361–1372

metabolic effects of, 1982: Nov., 1276–1280; 1983: July, 835–836

potassium balance and, 1981: March, 366, 376

regimens, alternatives, 1982: Nov., 1252–1261

in self-monitoring of blood glucose, 1982: Nov., 1235–1246

secretion, in diabetes mellitus, 1982: Nov., 1317–1319

prostaglandins and, 1981: July, 759–764 supplements, indications for, 1982: Nov., 1244–1246, 1259–1262

therapy, in ketoacidosis, 1983: July, 839–840; 1983: Nov., 1195–1196 in lactic acidosis, 1983: July, 826

Insulin-dependent diabetes (IDD), 1982: Nov., 1192–1193. See also Diabetes mellitus.

Insulin infusion device(s), portable, 1982: Nov., 1272–1274

Insulitis, 1982: Nov., 1214–1217 Intensive care. See under Critical

Intensive care. See under Critical care. Interferon, 1982: Jan., 236–237

human, 1983: Sept., 1147–1162 in viral respiratory infections, 1983: Sept., 1170

therapeutic uses of, 1983: Sept., 1154–1157

Intermittent positive-pressure breathing, 1983: May, 627

Intertrigo, candidal, 1982: July, 885–886
Intestinal infections, symposium on, 1982:
May, 557–762

Intestinal secretion, prostaglandins and, 1981: July, 778

Intestine(s). See also Bowel.

function during sleep, 1981: Nov. 1371–1372 migrating motor complex, 1981: Nov., 1311–1329

motility, disorders, symposium on, 1981: Nov., 1109–1411 Intestine(s), motility (Continued)
prostaglandins and, 1981: July, 775

obstruction of, in aged, 1983: March, 437–438

pseudo-obstruction syndromes, 1981: Nov., 1331–1358

Intoxication, drug, 1981: Jan., 28–31
Intra-aortic counterpulsation, 1981: Jan., 77–79

Intracranial tumors, 1981: Jan., 21–25
Intravenous alimentation, in critically ill,
1983: Nov., 1300

Intubation, endotracheal, in acute asthma, 1983: May, 678

in acute respiratory failure, 1983: May, 663-664

complications of, 1983: May, 729 with high-frequency ventilation, 1983: May, 637–638

Ion exchange system, 1983: July, 761–763, 776–777

IPPB, 1983: May, 627

Iritis, in recurrent herpes infection, 1983: Sept., 982

Iron, deficiency, in aged, 1983: March, 304–305

Irritable bowel syndrome, 1981: Nov., 1386–1391

behavioral therapy, 1981: Nov., 1402–1404

Ischemic heart disease, in aged, 1983: March, 384–386

Islet cell, destruction, in diabetic ketoacidosis, 1982: Nov., 1214–1217Isohydric principle, 1983: July, 772–775

Isolation, of viruses. See *Cell culture*. Isolation and susceptibility testing, for pathogens, 1982: Jan., 5–6

Isoniazid, 1982: Jan., 210–217; 1983: Jan., 81–82

disposition of, in liver disease, 1982: Jan.,

prophylaxis, 1983: Jan., 104–106 Isospora belli infection, treatment, 1982:

May, 713–714 Isotretinoin, oral, for acne, 1982: July, 864–866

Itch, pharmacologic control of, 1982: Sept., 1119–1133. See also Pruritus.

JOINT, disease, degenerative, in aged, 1982: Sept., 1047–1050

in aged, 1983: March, 524-530 inflammation. See specific disorders, as Rheumatoid arthritis; Gout.

KALIURESIS, 1981: March, 381

Kaposi's sarcoma, 1983: Jan., 238–240 cytomegalovirus infection and, 1983: Sept., 1099–1100

Keratitis, 1983: Jan., 145-146

Keratoconjunctivitis, epidemic, 1983: Sept., 986–987

Keratolytic agents, in psoriasis, 1982: July, 776–777

Keratoses, in aged, 1983: March, 537–540
 Ketoacidosis, diabetic, 1981: Jan., 117–132;
 1981: March, 326; 1983: July, 831–843;
 1983: Nov., 1193–1198

nondiabetic, 1983: July, 842

Ketoconazole, 1983: Jar.., 79 for fungal infections, 1982: Jan. 2

for fungal infections, 1982: Jan., 228–230; 1982: July, 889–890

Kidney(s). See also Renal. acute tubular necrosis, 1981: Jan., 147–163

ammoniagenesis and, 1983: July, 781–794 bicarbonate retention by, 1981: March, 334; 1983: July, 860–862

disease. See also specific disorders. chronic, hyponatremia with, 1981: March, 260–262

in aged, 1983: March, 463–480 dysfunction, drug-induced, 1983: Jan.,

123 effects of aldosterone on, 1983: July,

effects of aldosterone on, 1983: July, 879–881

failure, 1983: Nov., 1325–1341 acute, in aged, 1983: March, 473–474 prostaglandins and, 1981: July, 903–905

chronic, acidosis of, 1983: July, 845–858 in acute respiratory failure, 1983: May, 695–696, 734

in metabolic alkalosis, 1983: July, 904–905 obstructive disease, 1981: March, 419 parenchymal disease, acute, 1981: March,

potassium transport by, 1981: March, 368–373

role in ketoacidosis, 1983: July, 835 tubular acidosis and, 1983: July, 859–878 vascular regulation, prostaglandins and, 1981: July, 891–914

water excretion by, 1981: March, 256–259 Kinins, prostaglandins and, 1981: July, 884, 886

Kyphoscoliosis, respiratory muscle fatigue in, 1983: May, 588

Kyphosis, dorsal, in aged, 1983: March, 522

LABOR, induction of, prostaglandins and, 1981: July, 934 timing of, in diabetic pregnancy, 1982: Nov., 1337–1341 Laboratory, rapid viral diagnosis in, 1983: Sept., 953–972 virology, clinical uses of, 1983: Sept.,

935-951

Laboratory test(ing), in acid-base disorders, 1983: July, 802–804 in assessment of renal failure, 1983: Nov.,

1334–1335 office, 1983: Jan., 39–55

Lacrimal apparatus, infections, 1983: Jan., 146–147

Lactate, metabolic regulation of, 1983: July, 815–818

Lactic acidosis, 1981: March, 329; 1983: July, 815–829

Lactulose, for hepatic encephalopathy, 1981: Jan., 220

for shigellosis, 1982: May, 635

Lanolin, dermatitis from, 1981: Sept., 1085 Lasix. See Furosemide.

Lavage, gastric, in drug elimination, 1983: Nov., 1283

Laxative, chronic diarrhea due to, 1982: May, 605

for constipation, 1982: Sept., 1136-1139 LDL. See Low density lipoproteins (LDL).

Lecithin, dietary, effect on lipid metabolism, 1982: March, 499

Lecithin:cholesterol acyltransferase, cholesterol net transport and, 1982: March, 367–369

familial, 1982: March, 476–478 Lecithin: sphingomyelin ratio, in assessment of fetal lung maturity, 1982: Nov., 1335–1337

Leg, fungal infection, 1982: July, 880–881 Legionella, rifampin for, 1982: Jan., 161 Legionella pneumonia, 1983: Nov.,

1240-1241

Leprosy, rifampin for, 1982: Jan., 161 Leukemia, RNA viruses and, 1983: Sept., 1108–1110

T cell, treatment of, 1982: July, 895–913 Leukocyte(s), aggregation, in septic lung injury, 1983: May, 709–710

arachidonic acid metabolism and, 1981: July, 811, 818-821

disorders, drug-induced, 1983: Jan., 122 "lazy," 1981: Sept., 968

Leukotriene(s), in immediate hypersensitivity, 1981: Sept., 953

in septic lung injury, 1983: May, 704-705 Levamisole, for warts, 1982: July, 814

Levorphanol, for pain, 1982: Sept., 1062, 1094

Licorice, ingestion, aldosteronism and, 1983: July, 894

Liddle's syndrome, 1983: July, 894–895 Light eruption, polymorphous, 1982: July, 934–935 Lincomycin, 1982: Jan., 103-120

disposition of, in liver disease, 1982: Jan., 262

resistance to, 1982: Jan., 34

Lipids, dietary, effect on high density lipoprotein levels, 1982: March, 412-414 elevated levels, diabetes and, 1982: Nov., 1347-1360

metabolism, effect of alcohol on, 1982: March, 498

effect of calories on, 1982: March, 495 effect of dietary β-sitosterol on, 1982: March, 491

effect of dietary carbohydrates on, 1982: March, 495–497

effect of dietary cholesterol on, 1982: March, 486–490

effect of dietary fat on, 1982: March, 491

effect of dietary fiber on, 1982: March, 497

effect of dietary lecithin on, 1982: March, 499

effect of dietary protein on, 1982: March, 498

Lipoproteins, high density. See High density lipoproteins (HDL).

low density. See Low density lipoproteins (LDL).

metabolic abnormalities, in diabetics, 1982: Nov., 1348–1351

plasma, diet-induced alterations in, 1982: March, 377 very low density. See *Very low density li-*

poproteins (VLDL). Lipoprotein-lipid transport system, 1982:

March, 319–323

Lipoxygenase metabolites, in septic lung injury, 1983: May, 704–705

L-Thyroxine, in hypothyroidism, 1983: March, 507–508 Lithium, adverse effects of diuretics with,

1981: March, 300 in aged 1983: March 373-374

in aged, 1983: March, 373-374

Liver. See also Hepatic.

abscess, amoebic, 1982: May, 695–697 treatment, 1982: May, 710–712

cancer of, hepatitis B virus and, 1983: Sept. 1119–1121

disease. See also Hepatitis. drug disposition in, 1982: Jan., 257–266 encephalopathy with, 1981: Jan., 209–226

in aged, 1983: March, 436 lactic acidosis and, 1983: July, 822 renal tubular acidosis and, 1983: July,

with hypolipidemia, 1982: March, 480 failure, mixed acid-base disorders with, 1981: March, 357

Liver (Continued)

in low density lipoprotein metabolism, 1982: March, 343-345

therapy for familial hypercholesterolemia and, 1982: March, 355–358 inflammation. See *Hepatitis*.

reaction to drugs, 1981: Sept., 1096 role in ketoacidosis, 1983: July, 833–834

role in ketoacidosis, 1983: July, 833–834 Loop of Henle, bicarbonate reabsorption and, 1983: July, 755

Low density lipoproteins (LDL), atherogenesis and, 1982: March, 395–396 degradation, 1982: March, 346–351

high plasma levels, mechanisms, 1982: March, 346–351

metabolism in liver, 1982: March, 343-345

receptor defects, biochemical genetics of, 1982: March, 340–341

in cultured cells, 1982: March, 338–340 in familial hypercholesterolemia, 1982: March, 335–362

in vivo, 1982: March, 341-343

relation to very low density lipoproteins, 1982: March, 521

Loxoscelism, 1981: Jan., 241

Lung(s). See also Pulmonary.

abnormal gas exchange in, 1983: May, 557-571

age-related changes, 1983: March, 419–431 cell changes, in smokers, 1981: May, 667–689

disease, immunologic, eosinophils and, 1981: Sept., 1055-1071

obstructive, 1981: May, **455–706.** See also specific diseases.

airway responsiveness and, 1981: May, 473–487

cardiovascular performance in, 1981: May, 489–524

exercise performance in, 1981: May, 525–547

home oxygen in, 1981: May, **615–627** immune system in, 1981: May, 683–685

respiratory care for, 1981: May, 629-645

reversible, drug therapy in, 1981: May, 579-613

smoking and, 1981: May, 667-689 ventilatory requirements in, 1981: May, 532-535

occupational, airway obstruction in, 1981: May, 691-706

dysfunction, in sepsis, 1983: May, 701–703

peripheral, occupational exposure and, 1981: May, 694

elimination of carbon dioxide by, 1983: July, 915-917 Lungs (Continued)

gas exchange in, 1983: May, 625-626 infections. See also Pneumonia(s) and spe-

cific pathogens.

cephalosporins for, 1982: Jan., 189 in aged, 1983: March, 427–429 prophylaxis, 1983: Jan., 103–106 infiltrates with eosinophilia, 1981: Sept.,

1059-1069

injury, in ARDS, 1983: May, 689–690 prostaglandin metabolism in, 1981: July,

789-808

secretions, in smokers, 1981: May, 674-679, 683

volumes, in acute respiratory failure, 1983: May, 625

Lupus erythematosus, cutaneous, treatment of, 1982: July, 795–805 photosensitivity in, 1982: July, 935–936

systemic, 1981: Sept., 1097 Lyell's syndrome, 1981: Sept., 1098

Lyme arthritis, 1981: Jan., 182

Lymphocyte(s), age-related changes, 1983: March, 264

in airways of smokers, 1981: May, 673 Lymphogranuloma venereum, 1982: July,

922–924; 1983: Sept., 1065–1067 Lymphoma, cutaneous T cell, treatment of, 1982: July, 895–913

viruses and, 1983: Sept., 1110, 1115–1117 Lymphoproliferative disorders, 1981: Sept., 970

McARDLE's syndrome, 1981: Jan., 205

Macrodantin. See Nitrofurantoin.
Macrophage, pulmonary, in smokers, 1981:
May, 668, 679

Magnesium, deficiency, in Bartter's syndrome, 1983: July, 896

Magnesium balance, in chronic renal failure, 1981: March, 437

Majocchi's granuloma, 1982: July, 880–881 Malaria, prophylaxis, 1983: Jan., 109–110

Malignant disease. See also Carcinoma. hematologic, disorders of phagocytosis with, 1981: Sept., 968

immunodeficiency and, 1981: Sept., 960 Malnutrition, immunodeficiency and, 1981:

Sept., 970 protein-calorie, in acute respiratory failure, 1983: May, 739

with hypolipidemia, 1982: March, 479–480

Mannitol, 1981: March, 422

Mast cell(s), in asthma, 1981: Sept., 1015–1018

in immediate hypersensitivity reactions, 1981: Sept., 945–950 Maturity onset diabetes, 1982: Nov., 1197. See also Diabetes mellitus.

Mebendazole, for ascariasis, 1982: May, 727–728

for parasitic infections, 1982: Jan., 250 Mechanical ventilation. See Ventilation, mechanical.

Mediator(s), of lung injury, in ARDS, 1983: May, 689-690

of septic lung injury, 1983: May, 701–715, 718–719

mast cell, 1981: Sept., 1017

in drug reactions, 1981: Sept., 1092 of immediate hypersensitivity, 1981: Sept., 951–955

Medication(s). See *Drug*(s) or under specific medication.

Medicine, critical care, symposium on, 1983: Nov., 1179–1360

Melarsoprol, for parasitic infections, 1982: Jan., 248

Memory, disturbances, in aged, 1983: March, 349–351

with tricyclic antidepressants, 1982: Sept., 1042

Meningitis, bacterial, in aged, 1983: March, 278–282 prophylaxis, 1983: Jan., 100–101

rifampin for, 1982: Jan., 160 tuberculous, 1982: May, 755-762

Meningococcal pneumonia, 1983: Nov., 1242–1243

Meningococcal vaccine, 1983: Jan., 32 Meperidine, for pain, 1982: Sept., 1062,

1094 Mesenteric artery, occlusion of, in aged,

1983: March, 438–439 Metabolic acidosis. See Acidosis, metabolic. Metabolic alkalosis. See Alkalosis, metabolic

Metabolism, disordered, in diabetes mellitus, 1982: Nov., 1319–1320

Metaprotererol, 1981: May, 585–586 Meter(s), reflectance, for self-monitoring of blood glucose, 1982: Nov., 1230–1232

Methadone, for pain, 1982: Sept., 1062, 1094–1095

Methanol, lactic acidosis and, 1983, Inly, 824 Methenamine, 1982; Jan., 202–206, 1983; Jan., 77–78

Methicillin, resistance and tolerance to, 1982: Jan., 31

Methisazone, for viral infections, 1982: Jan., 241–242

Methotrexate, in psoriasis, 1982: July, 786–787

Methoxsalen, in psoriasis, 1982: July, 783–785

Methylphenidate, for narcolepsy, 1982: Sept., 980 Metoclopramide, for gastroesophageal reflux, 1981: Nov., 1229

Metolazone, 1981: March, 295

Metrifonate, for parasitic infections, 1982: Jan., 249

Metronidazole, 1982: Jan., 121–133, 247; 1983: Jan., 79–80

for antibiotic-associated pseudomembranous colitis, 1982: May, 660-661

for giardiasis, 1982: May, 712, 717 for intestinal amoebiasis, 1982: May, 709–711, 717

in nonspecific vaginitis, 1983: Jan., 230–231

in trichomoniasis, 1983: Jan., 228–229 Mezlocillin, 1982: Jan., 61–73

Miconazole, for fungal infections, 1982: Jan., 228–230; 1982: July, 891

Microbiology, office, 1983: Jan., 39–55 Microfilaria infestation, 1981: Sept., 1066 Microflora, intestinal, 1982: May, 557–574 Microscopy, in virus detection, 1983: Sept.,

954-956

Migrating motor complex, in small intestine, 1981: Nov., 1311–1329

Mineralocorticoid(s). See also Aldosterone. deficiency of, 1983: July, 831–890 excess of, 1983: July, 890–898 potassium balance and, 1981: March, 366

renal potassium excretion and, 1981: March, 372, 382 Mineralocorticoid therapy, in hypoaldoste-

ronism, 1983: July, 889-890 Minirotaviruses, 1982: May, 588

Mithramvein, 1981: March, 388

Mitral stenosis, in aged, 1983: March, 392–393

Molluscum contagiosum, 1982: July, 814–816; 1983: Jan., 246–247; 1983: Sept., 1065

eye signs, 1983: Jan., 138

Mongolism, immunodeficiency in, 1981: Sept., 1971

Monitoring, self-regulated, of blood glucose, 1982: Nov., **1227–1250**, 1259–1260, 1320

Monoamine oxidase inhibitors, in aged, 1983: March, 373

Monoclonal antibodies, viral, 1983: Sept., 963

Morphine, analgesia, in aged, 1982: Sept., 1080–1086

for pain, 1982: Sept., 1062, 1093–1094 pharmacokinetics of, 1982: Sept., 1086–1087

pharmacology of, 1982: Sept., 1061–1071 Motor complex, migrating, in small intestine, 1981: Nov., 1311–1329

Motor disorders, gastrointestinal, symposium on, 1981: Nov., 1109–1411

Motor neuron disorders, 1981: Jan., 189-207

Mounting, of specimens, 1983: Jan., 42 Moxalactam, 1982: Jan., 284–288

Mucociliary system, in asthma, 1981: Sept., 1020–1023

Mucus plugging, in asthma, 1981: Sept., 1020–1023

Muscle(s), of respiratory tract, performance of, 1983: May, 574–580

role in ketoacidosis, 1983: July, 834 smooth, arachidonic acid metabolites and, 1981: July, 815–818

Mustard, nitrogen, in cutaneous T cell lymphoma, 1982: July, 905-906

Myasthenia gravis, 1981: Jan., 201

Mycoplasma pneumonia, 1983: Nov., 1234 Mycoses, dermatologic, treatment of, 1982: July, 873–893

systemic, antimicrobial therapy for, 1982: Jan., 221-223

Mycosis fungoides, treatment of, 1982: July, 895–913

Myocardial infarction, prostaglandins and, 1981: July, 870

Myocardial ischemia, pain of, 1981: Jan., 55 Myotonic dystrophy, 1981: Nov., 1384 Myxedema. See also Hypothyroidism. Myxedema coma. 1983: Nov., 1203—1205

Myxovirus infection(s), in immunocompromised host, 1983: Sept., 1083

NAIL, candidal infection, 1982: July, 886 dystrophy, in psoriasis, 1982: July, 773 fungal infection, 1982: July, 881–882

Nalbuphine, for pain, 1982: Sept., 1063, 1095

Nalidixic acid, 1982: Jan., 199–206; 1983: Jan., 75–76 for shigellosis, 1982: May, 635

Naloxone, in drug elimination, 1983: Nov., 1284

Naproxen, for pain, 1982: Sept., 1057 Narcolepsy, 1982: Sept., 977–980 treatment for, 1982: Sept., 979–980

Narcotic drug(s), for pain, 1982: Sept., 1091-1104

in terminally ill, 1982: Sept., 1179–1182 in aged, 1982: Sept., 1079–1089 overdose, management of, 1983: Nov.,

pharmacology of, 1982: Sept., 1061–1071 relative potencies of, 1982: Sept., 1068–1071

side effects of, 1982: Sept., 1101–1102 Nasal disease, topical steroids in, 1981: Sept., 1078

Nasal polyps, 1981: Sept., 981

Nasopharyngeal carcinoma, Epstein-Barr virus and, 1983: Sept., 1117 Nausea, with narcotics, 1982: Sept., 1100 Necatur americanus infection, 1982: May, 731–733

Necrosis, acute tubular, renal failure and, 1983: Nov., 1329–1331

Neomycin, dermatitis from, 1981: Sept., 1084

for hepatic encephalopathy, 1981: Jan., 220

for hypercholesterolemia, 1982: March, 544

Neonate(s), chlamydial disease in, 1983: Sept., 1068–1069

conjunctivitis in, 1983: Jan., 143–144 herpes infection and, 1983: Sept., 1062–1063

Neoplastic disease. See Carcinoma; Malignant disease; Tumor(s); and specific disorders.

Nephritis, acute interstitial, 1981: March, 418

renal failure and, 1983: Nov., 1331–1332

Nephropathy, diabetic, hypertension and, 1982: Nov., 1377–1378

Nervous system, central, dysfunction, in aged, 1983: March, 345–359

in respiratory acidosis, 1983: July, 922–923

in respiratory alkalosis, 1983: July, 918–919

infections, cephalosporins for, 1982: Jan., 192–194

chloramphenicol for, 1982: Jan., 93-94

Neuralgia, postherpetic, 1982: July, 811 in aged, 1983: March, 533–534 treatment for, 1982: Sept., 1116–1117

Neurogenic bladder, in aged, 1983: March, 457–458

Neuroleptic drug(s), for pruritus, 1982: Sept., 1124–1125

for psychosis, 1982: Sept., 993–1009 relative potencies of, 1982: Sept., 995 side effects of, 1982: Sept., 1001–1005

Neurologic disorders, in aged, 1983: March, 339–341, 345–359

Neuromuscular disorders. See also specific disorders.

acute, 1981: Jan., 189-207

respiratory muscle fatigue in, 1983: May, 580-582, 588-589

Neuropathy, diabetic, effect of pump therapy on, 1982: Nov., 1277 sexual dysfunction and, 1982: Nov., 1389–1396

Neurotransmission, in gastrointestinal motility, 1981: Nov., 1129–1147 Neutropenia, congenital, 1981: Sept., 968 Neutrophil(s), aggregation, in septic lung injury, 1983: May, 709–710

polymorphonuclear, in airways of smokers, 1981: May, 671

Niclosamide, for parasitic infections, 1982: Jan., 248–249

for tapeworm infections, 1982: May, 739–740

Nicotinic acid, for hypercholesterolemia, 1982: March, 542–543

Nightmares, in adulthood, 1982: Sept., 985–986

Night terrors, 1982: Sept., 982-985

Niridazole, for parasitic infections, 1982: Jan., 249

Nitrofurantoin, 1982: Jan., 201–206; 1983: Jan., 76

pulmonary reactions to, 1981: Sept., 1064
Nitrogen mustard, in cutaneous T cell lymphoma. 1982: July, 905–906

Nocardia pneumonia, 1983: Nov., 1245-1246

Nocardiosis, trimethoprim-sulfamethoxazole for, 1982: Jan., 149

Nocturnal oxygen therapy trial, 1981: May, 616

Non-insulin-dependent diabetes (NIDD), 1982: Nov., 1193–1194. See also Diabetes mellitus.

Nonsteroidal anti-inflammatory drugs (NSAIDs), for pain, 1982: Sept., 1053-1059

in osteoarthritis, 1983: March, 528–529 Norepinephrine, prostaglandins and, 1981: July, 883

Norwalk-like virus, 1982: May, 576–580 Norwalk-like virus infection(s), gastroenteric, 1983: Sept., 1041–1046

Nose, anatomy and physiology of, 1981: Sept., 977

Nosocomial infection(s), 1983: Nov., 1251–1277

control of, 1983: Nov., 1259–1260, 1268–1270

morbidity and mortality of, 1983: Nov., 1255-1258

prevalence of, 1983: Nov., 1252–1255 risk factors of, 1983: Nov., 1258–1259 viral respiratory, 1983: Sept., 1018–1019

Nutrient(s), administration in critically ill, 1983: Nov., 1299–1300

dietary requirements, in aged, 1983: Mar., 296–298

Nutrition, in acute respiratory failure, 1981: May, 573

in acute tubular necrosis, 1981: Jan., 159 in aged, 1983: March, 295–313

in critically ill, 1983: Nov., 1295-1304

- Nutritional status, assessment of, in critically ill, 1983: Nov., 1297, 1338
 - infection and, 1983: Nov., 1297 maintenance of, in acute respiratory fail-
 - ure, 1983: May, 739–741 respiratory muscle fatigue and, 1983: May, 581–582
- Nutritional support, excessive, in critically ill, 1983: Nov., 1301–1302
 - monitoring of, in critically ill, 1983: Nov., 1300–1302
- OBESITY, diabetes and, 1982: Nov., 1196 effect on aging lung, 1983: March,
 - 426–427 effect on high density lipoprotein levels, 1982: March, 409–410
 - respiratory muscle fatigue in, 1983: May, 587–588
- Obesity-hypoventilation syndrome, 1983: May, 587–588
- Obstructive airways disease, eosinophils and, 1981: Sept., 1058
- reversible. See Asthma.

 Obstructive lung disease(s), 1981: May,
- 455–706. See also specific diseases. acute respiratory failure in, 1983: May, 657–668
- airway responsiveness and, 1981: May, 473-487
- cardiovascular performance in, 1981: May, 489–524
- chronic, acute respiratory failure in, 1981: May, 563–578
 - exercise performance in, 1981: May, 525-547
 - radiographic features of, 1983: Nov., 1310
 - respiratory care for, 1981: May, 629–645
- home oxygen in, 1981: May, 615–627 immune system in, 1981: May, 683–685 reversible, drug therapy in, 1981: May, 579–613
- smoking and, 1981: May, 667–689 ventilatory requirements in, 1981: May, 532–535
- respiratory muscle fatigue in, 1983: May, 585–587
- Occlusion, plastic, in psoriasis, 1982: July, 776
- Ocular infection(s), 1983: Jan., 131–152
 chloramphenicol for, 1982: Jan., 94
 viral, 1983: Sept., 973–990
- Office practice, microbiologic testing in, 1983: Jan., 39–55
- Oncogene(s), viral, 1983: Sept., 1121-1124

- Oncogenesis, viral, 1983: Sept., 1105-1127
- Oneirodynia, 1982: Sept., 985–986 Onvcholysis, in psoriasis, 1982: July, 773
- Onycholysis, in psoriasis, 1982: July, 773 Onychomycosis, 1982: July, 881–882
- Opiates, overdose, management of, 1983: Nov., 1289
- Organic mental syndrome, 1981: Jan., 10
- Organomercurials, 1981: March, 294 Organophosphates, over-lose, management of, 1983: Nov., 1289–1290
- Oropharyngeal dysphagia, 1981: Nov.,
- 1159–1167 Osmolality, regulation of, 1981: March,
- 251–253 Osteoarthritis, clinical, in aged, 1983:
- March, 525-529 in aged, 1982: Sept., 1047-1050
- Osteomyelitis, rifampin for, 1982: Jan., 160 Osteonecrosis, in aged, 1982: Sept., 1050–1051
- Osteoporosis, in aged, 1982: Sept., 1050; 1983: March, 519-524 putritional status and 1983: March
- nutritional status and, 1983: March, 301–303
- Otitis media, 1983: Jan., 164–166 acute, trimethoprim-sulfamethoxazole for, 1982: Jan., 148–149
- Ovary, disorders, in aged, 1983: March, 488–490
- Overdose, drug, management of, 1983: Nov., 1279–1293
- Overfeeding, in critically ill, 1983: Nov., 1301–1302
- Ovulation, prostaglandins and, 1981: July, 928
- Oxamniquine, for parasitic infections, 1982: Jan., 249
- Oxolinic acid, 1982: Jan., 199–206 for shigellosis, 1982: May, 635
- Oxycodone, for pain, 1982: Sept., 1062, 1094
- Oxygen, delivery of, in acute respiratory failure, 1983: May, 616–617 to tissues, 1983: May, 565, 569
- supplemental, during exercise training, 1981: May, 543
- therapy, home, 1981: May, 615-627 in acute respiratory failure, 1983: May, 660-661
- in cor pulmonale, 1981: May, 511 weaning from, 1981: May, 575
- Oxygenation, adult respiratory distress syndrome and, 1981: Jan., 38–42, 44
 - arterial, maintenance of, in acute respiratory failure, 1983: May, 615–616 of tissues, assessment of, 1983: May, 569
- Oxymorphone, for pain, 1982: Sept., 1063, 1094
- Oxytocin challenge test, in diabetic pregnancy, 1982: Nov., 1338

PACEMAKERS, temporary, 1981: Jan., 73–75 Pain, chronic, in aged, 1983: March, 352–353

control, consultation service, 1982: Sept., 1163–1168

in terminally ill, 1982: Sept., 1172–1173 with narcotics, in terminally ill, 1982: Sept., 1179–1182

with nonsteroidal anti-inflammatory drugs, 1982: Sept., 1053-1059 in aged, 1983: March, 334-335

narcotics for, 1982: Sept., 1061–1071, 1091–1104

relief, in aged, 1982: Sept., 1079–1089 Pancreas, disorders, in aged, 1983: March, 435

enzymes, prostaglandins and, 1981: July, 779

insulin secretion, 1982: Nov., 1251

Pancreatic cholera syndrome, 1982: May, 606–607

Panic, as reaction to illness, 1981: Jan., 5Papillomavirus, human, oncogenicity of, 1983: Sept., 1118–1119

Parabens, dermatitis from, 1981: Sept., 1085 Para-chloro-meta-xylenol (PCMX), 1981: Sept., 1085

Paracoccidioides brasiliensis, South American blastomycosis due to, 1982: May, 680–683

Parainfluenza virus infection(s), 1983: Sept., 1012–1013

nosocomial, 1983: Sept., 1019

Paralysis, periodic, potassium balance and, 1981: March, 376

Paramyxovirus infection(s), in immunocompromised host, 1983: Sept., 1083Parasitic infection(s), diagnosis of, 1983:

fan., 253–258

drugs for, 1982: Jan., 245–255. See also specific agent, such as *Metronidazole*. sexually transmitted, 1983: Jan., 247

Parathyroid gland(s), disorders, in aged, 1983: March, 492

Parkinson's disease, in aged, 1983: March, 355–356

voiding dysfunction and, 1983: March, 458–459

Paromomycin, for intestinal protozoan infections, 1982: May, 717 for tapeworm infections, 1982: May, 740

Paronychia, candidal, 1982: July, 886 Paroxysmal myoglobinuria, 1981: Jan., 205

Parturition, prostaglandins and, 1981: July, 932

Parvovirus(es), 1982: May, 589

Pathogens, isolation and susceptibility testing for, 1982: Jan., 5-6

Patient compliance, with insulin infusion therapy, 1982: Nov., 1288–1289 Patient education, in diabetes, 1982: Nov., 1293-1307

Patient selection, for continuous delivery of insulin, 1982: Nov., 1272–1274 psychological aspects of, 1982: Nov., 1286–1287

for meticulous control of diabetes, 1982: Nov., 1321-1322

Pavor nocturnus, 1982: Sept., 982-985

PCO₂, bicarbonate and, in regulation of pH, 1983: July, 800

in respiratory alkalosis, 1983: July, 917–922

bicarbonate buffer system and, 1983: July, 773

elevated, alkalosis and, 1983: July, 911–912

in respiratory acid-base disorders, 1983: July, 915–917

Pediculosis, eyelid infestation in, 1983: Jan., 138–139

PEEP. See Pressure, positive endexpiratory.

Pelvis, inflammatory disease of, 1983: Jan., 221–226

tetracyclines for, 1982: Jan., 299 Pemphigoid, bullous, in aged, 1983: March, 534

Penicillin, 1983: Jan., 61-62

Penicillin, anaphylactic reaction to, 1981: Jan., 228

antipseudomonas. See specific agent, such as Carbenicillin.

antistaphylococcal, 1982: Jan., 51–60. See also specific agent, such as Methicillin.

adverse reactions to, 1952: Jan., 56–57

resistance to, 1982: Jan., 51–52 disposition of in liver disease, 1982: Jan., 262–263

in gonorrhea, 1982: July, 916–917 in syphilis, 1982: July, 920

oral, adverse reactions to, 1983: Jan., 113–129

resistance to, 1982: Jan., 28–31 Penile prostheses, for diabetic impotence, 1982: Nov., 1393–1394

in aged, 1983: March, 456–457 Pentamidine, for parasitic infections, 1982:

Jan., 247–248 Pentazocine, for pain, 1982: Sept., 1063,

1095 Peptic ulcer disease, behavioral therapy for, 1981: Nov., 1402

in aged, 1983: March, 437 prostaglandins and, 1981: July, 782

Peptide(s), fibrin-derived, in septic lung injury, 1983: May, 707–708

Pericardiocentesis, 1981: Jan., 75-77

Pericardium, infections, cephalosporins for, 1982: Jan., 184–186

Perinatal risk, maternal diabetes and, 1982: Nov., 1326–1346

Peristalsis, radiography of, 1981: Nov., 1179–1180

Peritoneal dialysis, in psoriasis, 1982: July, 788

Pertussis vaccine, adverse reactions to, 1983: Jan., 19–20

pH. 1981: March. 348

ammoniagenesis and, 1983: July, 784–787 buffers and, 1983: July, 774–775

Henderson-Hasselbalch equation and, 1983: July, 799

in respiratory alkalosis, 1983: July, 917–922

urinary, in renal failure, 1983: July, 851 in renal tubular acidosis, 1983: July, 861–862

Phagocytosis, disorders of, 1981: Sept., 968 Pharmacodynamics, in aged, 1983: March, 323–325

Pharmacokinetics, in aged, 1983: March, 316–323

of antimicrobial drugs, 1983: Jan., 58–60 Pharmacology. See also Drug(s).

pharmacokinetic principles, in aged, 1982: Sept., 1073–1078

Pharyngitis, 1983: Jan., 153–158 viral, 1983: Sept., 1015–1016

Pharyngoconjunctival fever, 1983: Sept., 986–987

Pharyngoesophageal swallowing disorders, 1981: Nov., 1149–1171

Phencyclidine (PCP), overdose, management of, 1983: Nov., 1286–1287

Phenformin, lactic acidosis and, 1983: July, 822–823

Pheochromocytoma crisis, 1983: Nov., 1210–1212

Phosphate, balance, in chronic renal failure, 1981: March, 439, 442

buffer, 1983: July, 773–774 disorders, 1981: March, 393–399

therapy, 1981: March, 396 in ketoacidosis, 1983: Nov., 1195

Phosphatidylglycerol, in prenatal diagnosis of respiratory distress syndrome, 1982: Nov., 1336–1337

Phosphorylase deficiency, 1981: Jan, 205 Photochemotherapy, in cutaneous T cell

lymphoma, 1982: July, 906–907 in psoriasis, 1982: July, 783–785

Photodermatitis, drug-induced, 1981: Sept., 1094

Photoprotective agent(s), 1982: July, 936–937

Photosensitivity, cutaneous, treatment of, 1982: July, 927-939 Phototherapy, in psoriasis, 1982: July, 781–783

Physiotherapy, chest, 1981: May, 637 Pinworm infection, 1982: May, 729–731 Piperacillin, 1982: Jan., 61–73

Piperazine, for ascariasis, 1982: May, 726–727

for parasitic infections, 1982: Jan., 251 Piroxicam, for pain, 1982: Sept., 1058 Pituitary, acute vascular accident of, 1981: Jan., 105–116

Pituitary adenoma, 1981: Jan., 22

Pituitary gland, disorders. See also specific disorders, as *Cushing's disease*. in aged, 1983: March, 481–482

Pituitary gonadotrophin secretion, prostaglandins and, 1981: July, 927

Pityriasis versicolor, 1982: July, 877–878
Placebo effects, in treatment of dementia, 1982: Sept., 1155–1156

Plague, pneumonia and, 1983: Nov., 1241–1242

prophylaxis, 1983: Jan., 110 Plasmids, in resistance to antimicrobial ther-

apy, 1982: Jan., 26–28 Platelet(s), aggregation, in septic lung injury, 1983: May, 708–709

disorders, drug-induced, 1983: Jan., 122-123

hemorrhage with, 1981: Jan., 135 functions, prostaglandins and, 1981: July, 860–867

vessel wall interactions, prostaglandins and, 1981; July, 855–880

Platelet-activating factors, 1981: Sept., 954 Pneumococcal pneumonia, 1983: Nov., 1233–1236

Pneumococcal vaccine, 1983: Jan., 30–32 Pneumocystis carinii infection(s), trimethoprim-sulfamethoxazole for, 1982: Jan.,

Pneumocystis pneumonia, 1983: Nov., 1246
Pneumonia(s). See also specific pathogens.
atypical, tetracyclines for, 1982: Jan., 299
bacterial, in aged, 1983: March, 274–278
in aged, 1983: March, 427–428
eosinophilic, 1981: Sept., 1063–1064, 1096
gram-negative, 1983: Nov., 1236–1237
nosocomial, 1983: Nov., 1260–1270
in acute respiratory failure, 1983: May,

737–738 overwhelming, 1983: Nov., **1233–1249** pneumococcal, 1983: Jan., 180–181 radiographic features of, 1983: Nov., 1310–1311

viral, 1983: Sept., 1017

Pneumoperitoneum, in acute respiratory failure, 1983: May, 731

Pneumothorax, radiographic features of, 1983: Nov., 1317–1321

Poisoning, management of, 1983: Nov., 1279–1293. See also under specific agent, as Cyanide.

Poliomyelitis, respiratory muscle fatigue in, 1983: May, 581

Poliomyelitis vaccine, oral, 1983: Jan., 20–21Poliovirus infection(s), in homosexual men,1983: Sept., 1101

Polyarteritis nodosa, 1982: July, 949–951 Polydipsia, psychogenic, 1981: March, 312 Polymyxin, in control of nosocomial pneu-

monia, 1983: Nov., 1269

Polymyxin B, 1982: Jan., 135–142
 Polymyalgia rheumatica, 1981: Jan., 203 in aged, 1982: Sept., 1051

Polymyositis, 1981: Jan., 196

Polyneuritis, acute infective, 1981: Jan., 194 Polyps, nasal, 1981: Sept., 981

Polyuria, 1981: March, 303-313

Popliteal artery, aneurysm of, 1981: Jan., 91 Porphyria(s), photosensitivity and, 1982: July, 931–933

Portasystemic encephalopathy, 1981: Jan., 217

Positive end-expiratory pressure. See Pressure, positive end-expiratory.

Potassium, balance, ammoniagenesis and, 1983: July, 787–792

in acid-base disorders, 1983: July, 802–803

in chronic renal failure, 1981: March, 433-435

in hyperaldosteronism, 1983: July, 896 in hypoaldosteronism, 1983: July, 881–890, 897

in metabolic alkalosis, 1983: July, 906 in renal failure, 1983: Nov., 1337–1338

in renal tubular acidosis, 1983: July, 864, 874–876 depletion, diuretic-induced, 1981: March,

300 hyponatremia with, 1981: March,

260–262 disorders, 1981: March, 374–384

in acute tubular necrosis, 1981: March, 424

gastrointestinal excretion of, 1981: March, 383

homeostasis, 1981: March, 363–384 iodide, for sporotrichosis, 1982: Jan., 221 replacement, in ketoacidosis, 1983: July, 841: 1983: Nov., 1194

in metabolic alkalosis, 1983: July, 909 renal excretion of, 1981: Jan., 166 renal transport of, 1981: March, 368–373 serum, in mixed acid-base disorders,

serum, in mixed acid-base disorders, 1981: March, 353

Prausnitz-Küstner reaction, 1981: Sept., 946 Pregnancy, asthma and, 1983: May, 682 diabetes and, glycemic control in, 1982: Nov., 1232–1233 Pregnancy, diabetes and (Continued) management of, 1982: Nov., 1325–1346 herpes infections during, 1983: Sept., 1062–1063

hyperlipidemia of, diet therapy for, 1982: March, 504–505

multiple insulin injections during, 1982: Nov., 1263

onset of diabetes during, 1982: Nov., 1194–1195

Pressure, blood. See *Blood pressure*. central venous. See *Venous pressure*.

continuous positive airway, in mechanical ventilation, 1983: May, 605–612 physiology of, 1983: May, 627–628

intrathoracic vascular, respiratory effects on, 1983: Nov., 1354–1355

pulmonary artery, monitoring of, in critically ill, 1983: Nov., 1348–1358

positive end-expiratory, depressed cardiac output and, 1983: May, 735-736 in ARDS, 1983: May, 692-693 in mechanical ventilation, 1983: May,

601–617 physiology of, 1983: May, 627 pulmonary arterial wedge, 1981: May,

490, 538
monitoring of, in critically ill, 1983:

Nov., 1348–1358 Primaquine, for parasitic infections, 1982: Jan., 246

Probenicid, 1981: March, 409 Probucol, for hypercholesterolemia, 1982: March, 545

Proctitis, in homosexual men, 1983: Jan., 236–238

Propionic acid, derivatives, for pain, 1982: Sept., 1056–1057

Propoxyphene, for pain, 1982: Sept., 1094–1095

Propranolol, for variceal bleeding, 1983: Nov., 1222

Propylene glycol, dermatitis from, 1981: Sept., 1085

Prostaglandins, cytoprotective effects of, 1981: July, 779–781 gastrointestinal effects and, 1981: July,

773–787 glucose homeostasis and, 1981: July,

759–771 in immediate hypersensitivity, 1981: Sept., 955

in septic lung injury, 1983: May, 703–704 insulin secretion and, 1981: July, 759–764 metabolism in lungs, 1981: July, 789–808 peptic ulcer disease and, 1981: July, 782 pro-inflammatory actions of, 1981: July, 724 synthesis, arachidonic acid metabolism in,

1981: July, 716–720 inhibitors of, anti-inflammatory agents

inhibitors of, anti-inflammatory age as, 1981: July, 713–757 Prostate, cancer of, in aged, 1983: March, 448–449

hypertrophy of, in aged, 1983: March, 445-448

Prostatitis, 1983: Jan., 197–198 tetracyclines for, 1982: Jan., 299 trimethoprim-sulfamethoxazole for, 1982: Jan., 148

Prosthesis, penile, for diabetic impotence, 1982: Nov., 1393–1394 in aged, 1983: March, 456–457

Protease inhibitor(s), in obstructive lung diseases, 1981: May, 455

Protein(s), antiviral, 1983: Sept., 1147–1162 dietary, effect on lipid metabolism, 1982: March, 498

in lung secretions of smokers, 1981: May, 675

Protein buffers, 1983: July, 774

Protein-calorie malnutrition, in acute respiratory failure, 1983: May, 739

Proton transport, in urinary acidification, 1983: July, 753–763

Protozoan infection(s), treatment, 1982: May. 707–720

Pruritus, in aged, 1983: March, 535–536 in terminally ill, 1982: Sept., 1177 methods of physical therapy for, 1982: Sept., 1122–1123

nocturnal, in scabies, 1982: July, 955–957 pharmacologic control of, 1982: Sept., 1119–1133

Pseudo-Bartter's syndrome, prostaglandins and, 1981: July, 901

Pseudogout, in aged, 1982: Sept., 1051 Pseudohypertension, in aged, 1983: March, 404-405

Pseudohyponatremia, 1981: March, 251 Pseudohyperaldosteronism, 1983: July, 894–895

Pseudohypoparathyroidism, 1981: March, 390 Pseudomembranous colitis, antibiotic-associated, 1982: May, 655–664

Pseudomonas infections, penicillins for, 1982: Jan., 69–70. See also specific agent, such as Carbenicillin.

Pseudo-obstruction syndromes, chronic intestinal, 1981: Nov., 1331–1358

Pseudo-parkinsonian reaction, to neuroleptics, 1982: Sept., 1002–1003

Psoralen, ultraviolet light and, in cutaneous T cell lymphoma, 1982: July, 906–907 in psoriasis, 1982: July, 783–785

Psoriasis, treatment of, 1982: July, 769–794 Psychiatric syndromes, in aged, 1983: March, 361–377

Psychogenic polydipsia, 1981: March, 312Psychological aspects, of insulin infusion pumps, 1982: Nov., 1285–1292

Psychopharmacologic drugs, in aged, 1983: March, 369–374 Psychosis, drug therapy for, 1982: Sept., 993–1009

Psychotherapy, in aged, 1983: March, 369 Psychotic reaction, to acute illness, 1981: Jan., 6

Pulmonary. See also Lung(s).

Pulmonary arterial wedge pressure, 1981: May, 490, 538

monitoring of, in critically ill, 1983: Nov., 1348–1358

Pulmonary artery hypertension, in obstructive lung disease, 1981: May, 489–495

Pulmonary aspiration, gastroesophageal reflux and, 1981: Nov., 1204–1208

Pulmonary circulations, prostaglandins in, 1981: July, 798

Pulmonary complications, of acute respiratory failure, 1983: May, 694–695, 725–729

Pulmonary disease, chronic obstructive, radiographic features of, 1983: Nov., 1310

respiratory muscle fatigue in, 1983: May, 585–587

infiltrative, eosinophilic, 1981: Sept., 1059–1069

interstitial, respiratory muscle fatigue in, 1983: May, 588

obstructive, 1981: May, 455–706. See also specific diseases.

acute respiratory failure in, 1983: May, 657-668

airway responsiveness and, 1981: May, 473–487

cardiovascular performance in, 1981: May, 489–524

chronic, acute respiratory failure in, 1981: May, 563–578 respiratory care for, 1981: May, 629–645

exercise performance in, 1981: May, 525-547

home oxygen in, 1981: May, 615–627 immune system in, 1981: May, 683–685 immunologic aspects of, 1981: Sept., 1055–1059

reversible, drug therapy in, 1981: May, 579–613

smoking and, 1981: May, 667–689 ventilatory requirements in, 1981: May, 532–535

occupational, airways obstruction in, 1981: May, 691–706

Pulmonary edema, permeability, 1981: Jan., 36

radiographic features of, 1983: Nov., 1311–1312

Pulmonary embolism, acute massive, 1983: Nov., 1181–1185

in acute respiratory failure, 1981: May, 573; 1983: May, 694-695, 725-727;

Pulmonary embolism (Continued) 1983: Nov., 1179–1191 pain of, 1981: Jan., 60

radiographic features of, 1983: Nov., 1315–1316

Pulmonary emphysema. See Emphysema. Pulmonary function, age-related changes, 1983: March, 419–431

Pulmonary hypertension, in chronic airflow obstruction, 1981: May, 554

Pulmonary infection(s), in aged, 1983: March, 427–429

nosocomial, in acute respiratory failure, 1983: May, 737–738

prophylaxis, 1983: Jan., 103–106 Pulmonary injury, in ARDS, 1983: May, 689–690

septic, mediators of, 1983: May, 701–715 Pulmonary management, of overdose patient, 1983: Nov., 1282

Pulmonary nodules, in aged, 1983: March, 426

Pulmonary radiology, in critical care medicine, 1983: Nov., 1305–1324

Pulmonary vascular resistance, 1981: May, 490, 492

Pump. See also under *Insulin*, *delivery*. for insulin infusion, 1982: Nov., 1269–1283

psychological reactions to, 1982: Nov., 1285–1292

Purpura fulminans, 1981: Jan., 239 PUVA. See *Psoralen*.

Pyloric sphincter, motility of, effect of gastrointestinal hormones on, 1981: Nov., 1117–1118

Pyrantel, for ascariasis, 1982: May, 726–728 for parasitic infections, 1982: Jan., 251 Pyrazoles, for pain, 1982: Sept., 1055

Pyrimethamine, for parasitic infections, 1982: Jan., 246–247

Pyroles, for pain, 1982: Sept., 1055–1056 Pyruvate, role in lactate metabolism, 1983: July, 815–818

Pyruvate dehydrogenase deficiency, lactic acidosis and, 1983: July, 824

Pyrvinium pamoate, for parasitic infections, 1982: Jan., 251

Q FEVER, 1983: Nov., 1241 Quaternium 15, dermatitis from, 1981: Sept., 1085

Quinacrine, for giardiasis, 1982: May, 712, 717–718

for tapeworm infections, 1982: May, 740

RABIES vaccine, 1983: Jan., 32–33 Radioactive iodine therapy, for hyperthyroidism, 1983: Mar., 502–503 Radiographic examination, pulmonary, in critical care medicine, 1983: Nov., 1305–1324

Radioimmunoassays, in virus detection, 1983: Sept., 961–962

Radionuclide scan(s), in herpes simplex encephalitis, 1983: Sept., 998 in pulmonary embolism, 1983: Nov., 1184–1185

Radiotherapy, in cutaneous T cell lymphoma, 1982: July, 907–908

Ragweed pollen, desensitization to, allergoid in, 1981: Sept., 983-984

Rash, drug-induced, 1981: Sept., 1093Reagent strips, for glucose measurement, 1982: Nov., 1229–1230

Reagent(s), viral immune, 1983: Sept., 962-963

Reagin-dependent hypersensitivity, 1981: Sept., 941

Reflectance meter(s), for self-monitoring of blood glucose, 1982: Nov., 1230-1232

Reflux, enterogastric, 1981: Nov., 1278–1279 gastroesophageal, 1981: Nov., 1195–1222, 1223–1234

Regressive dependency, reaction to acute illness, 1981: Jan., 7

Renal See also *Kidney*.

Renal compensation, in acid-base balance,

1983: July, 778–779 Renal disease, diabetic hypertension and, 1982: Nov., 1377–1378

drug-induced, 1983: Jan., 123 hypoaldosteronism and, 1983: July, 883 in aged, 1983: March, 463–480

pruritus in, 1982: Sept., 1127–1128 Renal failure, acidosis of, 1981: March, 326 acute, 1981: March, 267; 1983: Nov.,

1325–1341 classification of, 1983: Nov., 1326–1333 diagnosis of, 1983: Nov., 1333–1337 hyponatremia of, 1981: March, 267 in aged, 1983: March, 473–474 management of, 1983: Nov., 1337–1339 oliguria and, 1981: March, 413–427 prostaglandins and, 1981: July, 903–905 tubular necrosis and, 1981: Jan., 147–163

chronic, 1981: March, 429–447 hyperuricemia in, 1981: March, 404 hyperkalemia of, 1981: March, 377 hyperuricemia in, 1981: March, 404 hypocalcemia of, 1981: March, 392 in acute respiratory failure, 1983: May, 695–696, 734

Renal failure index, 1983: Nov., 1336 Renal function, age-related changes, 1983: March, 465–469

Renal insufficiency, antimicrobial therapy and, 1982: Jan., 267–281 dialysis in, 1982: Jan., 272–274 Renal mechanisms, of metabolic alkalosis, 1983: July, 905–908

Renal necrosis, acute tubular, 1981: Jan., 147-163

Renal parenchymal disease, acute, 1981: March, 416–418

Renal sites, of urinary acidification, 1983: July, 763–767

Renal tissue, diseased, antimicrobial pharmacokinetics in, 1982: Jan., 275–278

Renal tubular acidosis, 1983: July, 859–878. See also under Acidosis.

potassium depletion and, 1981: March, 382

Renal tubular necrosis, acute, 1981: March, 419–423

Renal vascular regulation, prostaglandins and, 1981: July, 891–914

Renal water reabsorption, prostaglandins and, 1981: July, 918–922

Renin, deficiency of, hypoaldosteronism and, 1983: July, 883–885

Renin release, renal, prostaglandins and, 1981: July, 892Reproduction, prostaglandins in, 1981: July,

927–936
Reset osmostat, 1981: March, 266
Resei(s) hile soid hinding, for hypershy

Resin(s), bile-acid binding, for hypercholesterolemia, 1982: March, 540–542

Resistance, to antimicrobial therapy, 1982: Jan., 25–37. See also under specific agent.

combination therapy for preventing, 1982: Jan., 20-21

Respiration, depressed, with narcotics, 1982: Sept., 1099-1100

disordered. See also Respiratory failure. in aged, 1983: March, 422–425 spontaneous, physiology of, 1983: May,

622–623
Respiratory. See also Lung.

Respiratory alkalosis. See Acidosis, respiratory.

Respiratory alkalosis. See Alkalosis.

Respiratory alkalosis. See Alkalosis, respiratory.

Respiratory care, comprehensive, for chronic obstructive lung disease, 1981: May, 629-645

Respiratory compensation, in acid-base disorders, 1983: July, 778–779, 801 in metabolic alkalosis, 1983: July, 809

Respiratory distress syndrome, adult, 1981: Jan., 33–51; 1983: May, 685–700 complications of, 1983: May, 694–696 corticosteroids in, 1983: May, 717–724 high-frequency ventilation in, 1983: May, 639

radiographic features of, 1983: Nov., 1311–1312

neonatal, maternal diabetes and, 1982: Nov., 1336–1338 Respiratory failure, acid-base imbalance in, 1983: May, 645–656

acute, classification, 1983: May, 551–556 complications of, 1983: May, 725–746 in ARDS, 1983: May, 685–700 in chronic obstructive lung disease, 1981: May, 563–578; 1983: May,

1981: May, 363–378; 1983: May, 657–668

mechanical ventilation in, 1983: May,

599–619 radiographic features of, 1983: Nov.,

1309–1316 complications of, radiographic features of,

1983: Nov., 1316–1321 in asthmatics, 1983: May, 669–684 muscle fatigue and, 1983: May, 573–597

pulmonary embolism and, 1983: Nov., 1179–1191

sepsis and, 1983: May, 701–715 symposium on, 1983: May, 551–746 Respiratory muscle training, in obstructive

lung disease, 1981: May, 541–543 Respiratory syncytial virus infection(s), 1983: Sept., 1014

nosocomial, 1983: Sept., 1019 Respiratory tract, age-related changes, 1983: March, 4!9–431

gas exchange in, 1983: May, 557–571 impaired diffusion in, 1983: May, 558–559 infections. See also Lung(s), infection(s);

Pneumonia(s); and specific pathogens. airway reactivity and, 1981: Sept., 1045–1053

drugs for, 1983: Sept., 1167–1170 lower, infections, 1983: Jan., 173–186 nosocomial infections, 1983: Nov., 1260–1270

muscles of, failure of, 1983: May, 573–597 upper, infections, 1983: Jan., 153–171 viral infections, 1983: Sept., 1009–1030

Restlessness, in the terminally ill, 1982: Sept., 1178

Retinopathy, diabetic, effect of pump therapy on, 1982: Nov., 1279–1280

Retrovirus(es), oncogenic, 1983: Sept., 1106–1111 Rheumatic fever, prophylaxis, 1983: Jan.,

101–103
Rheumatic syndromes, in aged, 1982: Sept.,

1047–1052

Pharmatrial arthritis arrabidania acid ma

Rheumatoid arthritis, arachidonic acid metabolites and, 1981: July, 822

Rheumatoid factor, interference in IgM assays, 1983: Sept., 945–946, 964 Rhinitis, 1981: Sept., 977–986

Rhinitis medicamentosa, 1981: Sept., 980

Rhinophyma, in rosacea, 1982: July, 824–826

Rhinovirus infection(s), respiratory, 1983: Sept., 1013–1014

Ribavirin, in viral respiratory infections, 1983: Sept., 1169–1170

Rickets, vitamin D-resistant, 1981: March, 394

Rifampin, 1982: Jan., 157–168, 210–216; 1983: Jan., 80–81

disposition of, in liver disease, 1982: Jan., 263

for tuberculosis, 1982: Jan., 209–217 Right ventricular hypertrophy, 1981: May,

Rimantadine, in viral respiratory infections, 1983: Sept., 1167–1169

Ringworm, of body, 1982: July, 882–884 of scalp, 1982: July, 881

RNA virus(es), oncogenic, 1983: Sept., 1106–1111

Rosacea, steroid-induced, 1981: Sept., 1986
 treatment of, 1982: July, 822–826
 Rotavirus(es), 1982: May, 580–587

Rotavirus infection(s), gastroenteric, 1983: Sept., 1032–1041

Rotavirus vaccine, 1983: Sept., 1041 Roundworm infection, drug therapy for, 1982: May, 724–729

Rumination syndrome, behavioral therapy for, 1981: Nov., 1398–1401

Salicylates, as prostaglandin synthesis inhibitors, 1981: July, 737–742, 745–748 for pain, 1982: Sept., 1054–1055 for pruritus, 1982: Sept., 1125 lactic acidosis and, 1983: July, 824 urticaria and, 1982: July, 834–835

Salicylic acid, in acne, 1982: July, 857 Saline therapy, in ketoacidosis, 1983: July, 839

in metabolic alkalosis, 1983: July, 908–909 Salmonellosis, chloramphenicol for, 1982: jan., 93

trimethoprim-sulfamethoxazole for, 1982: Jan., 149

Salpingitis, 1983: Jan., 221-226

Sarcoma, Kaposi's, 1983: Jan., 238–240 RNA viruses and, 1983: Sept., 1106–1107, 1110

Scabies, 1983: Jan., 247
 management of, 1982: July, 955–963
 Scalded skin syndrome, 1981: Jan., 232

Scalp, fungal infection, 1982: July, 881 Scan(s), perfusion lung, in pulmonary embo-

lism, 1983: Nov., 1184–1185 Schizophrenia, drug treatment for, 1982: Sept., 996–1000

in aged, 1983: March, 364–366 Scintigraphy, in evaluation of esophagus, stomach, and duodenum, 1981: Nov., 1291–1310 Sclerosis, endoscopic, for variceal bleeding, 1983: Nov., 1221–1222 progressive systemic, 1981: Nov., 1383

Screening, for diabetes, 1982: Nov., 1197–1199

Seborrhea, treatment of, 1982: July, 826-829

Secretory component, in lung secretions of smokers, 1981: May, 677

Secretory diarrheas, pathophysiology, 1982: May, 597–610

prophylaxis and therapy, 1982: May, 611–621

Sedative(s), for pruritus, 1982: Sept., 1124 overdose, management of, 1983: Nov., 1288–1289

with narcotics, 1982: Sept., 1099 with tricyclic antidepressants, 1982: Sept., 1042

Seizure(s), grand mal, lactic acidosis and, 1983: July, 822

in herpes simplex encephalitis, 1983: Sept., 1002

Sepsis, in acute respiratory failure, 1983: May, 701–715, 737

lactic acidosis and, 1983: July, 822 Septic arthritis, 1981: Jan., 183

Septic shock, corticosteroids in, 1983: May, 717–724

pulmonary injury and, 1983: May, 701-715

Serologic tests, in diagnostic virology, 1983: Sept., 944–948, 963–966

in herpes simplex encephalitis, 1983: Sept., 994–996

Serotonin, in immediate hypersensitivity, 1981: Sept., 955

Serum sickness, drug-induced, 1981: Sept., 1093

penicillin-induced, 1983: Jan., 120–121
Sexual dysfunction, in male diabetics, 1982:
Nov., 1389–1396

Sexual function, in aged, 1983: March, 453–457

Sexually transmitted diseases, in men, 1983: Jan., 235–251

in women, 1983: Jan., 221–234 prophylaxis, 1983: Jan., 102 treatment of, 1982: July, 915–925 viral, 1983: Sept., 1059–1073

in homosexual men, 1983: Sept.,

Sézary syndrome, treatment of, 1982: July, 895–913

Shampoo(s), for seborrhea, 1982: July, 829
Shigella, properties of virulence, 1982: May, 624–629

Shigellosis, 1982: May, 623-638

trimethoprim-sulfamethoxazole for, 1982: Jan., 149 Shingles, 1982: July, 810-812. See also Herpes zoster.

Shock, respiratory distress syndrome after, 1981: Jan., 34

septic. See Septic shock.

Shunt(s), intrapulmonary, effect on gas exchange, 1983: May, 560-562

Sinus, cavernous, thrombosis of, 1983: Jan., 148

Sinusitis, 1983: Jan., 158-164 chronic, 1981: Sept., 981

β-Sitosterol, dietary, effect on lipid metabolism, 1982: March, 491

for hypercholesterolemia, 1982: March, 543-544

Skin, age-related changes, 1983: March, 532-533

cancer, in aged, 1983: March, 537-541 complications, with intravenous delivery of insulin, 1982: Nov., 1281-1282

disorders, in aged, 1983: March, 342, 531-543

life-threatening, 1981: Jan., 227-243 treatment of, 1982: July, 769-963. See also under specific diseases, as Psoriasis

in rheumatic diseases. See specific diseases.

lesions, in lupus erythematosus, 1982: July, 795-805

reactions, to antibiotics, 1983: Jan., 118-120

viral infection, treatment of, 1982: July, 807-817

SLE. See Lupus erythematosus, systemic. Sleep, disorders, in aged, 1983: March, 348-349

> in chronic airflow obstruction, 1981: May, 549-561

treatment for, 1982: Sept., 971-991 gastrointestinal function during, 1981: Nov., 1359-1376

physiology, 1981: May, 549

Sleep apnea, 1981: May, 558; 1982: Sept., 980-982

in aged, 1983: March, 424

treatment for, 1982: Sept., 981-982 Sleepwalking, 1982: Sept., 982-985

Slow-reacting substance of anaphylaxis (SRS-A), in immediate hypersensitivity, 1981: Sept., 953

Smallpox vaccine, 1983: Jan., 18-19

Smoking, airway changes due to, 1981: May, 667-689

airway reactivity and, 1981: May, 481 elastase-antielastase hypothesis and, 1981: May, 653

gastroesophageal reflux and, 1981: Nov., 1224

Sodium, balance, in acute tubular necrosis, 1981: March, 423

Sodium, balance (Continued)

in chronic renal failure, 1981: March.

in respiratory failure, 1983: May, 654-655

intake, renal potassium excretion and, 1981: March, 371

intoxication, 1981: March, 277

low, clinical manifestations of, 1981: March, 259-269

reabsorption, aldosterone and, 1983: July, 880-881

in renal tubular acidosis, 1983: July, 869-870

serum concentrations, high. See Hupernatremia.

low. See Huponatremia.

osmotic forces and, 1981: March, 251 Sodium bicarbonate, diuresis, 1981: March,

for metabolic acidosis, 1981: March, 331-333

Sodium chloride diuresis, 1981: March, 307 Sodium colistimethate, 1982: Jan., 135-142 Sodium-hydrogen exchange mechanisms, 1983: July, 761-762

Solar urticaria, 1982: July, 841 Solute diuresis, 1981: March, 306-310

Somnambulism, 1982: Sept., 982-985 South American blastomycosis, 1982: May, 680-683

Specimen, collection techniques, 1983: Jan., 39-40

for viral culture, 1983: Sept., 936-944 Spectinomycin, 1982: Jan., 169-173 Spider bites, 1981: Jan., 241

Spinal cord, lesions of, respiratory muscle fatigue in, 1983: May, 580-581, 588-589

Spironolactone, 1981: March, 296 in hyperaldosteronism, 1983: July, 892-893

Splenic artery, aneurysm of, 1981: Jan., 94 Sporotrichosis, potassium idodide for, 1982:

Sprue, tropical, 1982: May, 13-15

Sputum cultures, 1983: Jan., 44-46, 179-180 Staging, of cutaneous T cell lymphoma, 1982: July, 900-905

Staphylococcal infections, penicillins for. See Penicillin(s), antistaphylococcal.

Staphylococcal pneumonia, 1983: Nov., 1237-1238

Staphylococcus aureus, enterotoxigenic, 1982: May, 605

Status asthmaticus, 1983: May, 675 Steroid(s). See also Corticosteroid(s).

in acne, 1982: July, 862-863

in etiology of perioral dermatitis, 1982: July, 820-821

Steroid(s) (Continued) in seborrhea, 1982: July, 828–829 Stimulants, in aged, 1983: March, 372 Stomach, acid secretion during sleep, 1981: Nov., 1367–1371 cancer of in aged, 1983: March, 440

Nov., 1367–1371 cancer of, in aged, 1983: March, 440 disorders, in aged, 1983: March, 435 motility, disorders, 1981: Nov., 1269–1289 effect of gastrointestinal hormones, 1981: Nov., 1115–1117 prostaglandins and, 1981: July, 775

Stool cultures, 1983: Jan., 52 Streptococcal pneumonia, 1983: Nov., 1233–1234

Streptokinase, for pulmonary embolism, 1983: Nov., 1186-1187

Streptomycin, for tuberculosis, 1982: Jan., 209-217

Stress ulcer(s), bleeding from, 1983: Nov., 1222–1225 prophylaxis, 1983: Nov., 1224–1225

prophylaxis, 1963: Nov., 1224-1225 Stroke. See *Transient ischemic attack(s)*. Strongyloidiasis, 1982: May, 733-735

in immunocompromised patient, 1982: May, 750–752 Stye, 1983: Jan., 135

Sudden death, prostaglandins and, 1981: July, 870

Sulfamethoxazole. See Trimethoprimsulfamethoxazole.

Sulfinpyrazone, 1981: March, 409 Sulfonamide(s), 1983: Jan., 71–72 resistance to, 1982: Jan., 33

Sulfone(s), in acne, 1982: July, 862–863 Sulindac, for pain, 1982: Sept., 1056 Sun, cutaneous reaction to, treatment of

Sun, cutaneous reaction to, treatment of, 1982: July, 927–939 Sunburn, 1982: July, 928–929

Sunscreens, 1982: July, 936–937 Suramin, for parasitic infections, 1982: Jan., 248

Surgery, for acne, 1982: July, 866 for pulmonary emboli, 1983: Nov., 1187–1190

for warts, 1982: July, 812 insulin management during, 1982: Nov., 1361–1372

Swallowing, disorders, pharyngoesophageal, 1981: Nov., 1149–1171

during sleep, 1981: Nov., 1364–1366 normal, 1981: Nov., 1235–1241

Swan-Ganz catheter hemodynamic monitoring, 1981: Jan., 69–73 in critically ill, 1983: Nov., 1348–1358

in critically ill, 1983: Nov., 1348–1358 in respiratory failure, complications of, 1983: May, 728

Swine influenza vaccine, adverse reactions to, 1983: Jan., 21

Sykes-Matthews classification, of beta-lactamases, 1982: Jan., 29–30 Sympathetic inhibitor agents, effects, in diabetics, 1982: Nov., 1381–1382 Sympathomimetic bronchodilators, 1981:

May, 580–587

Symptom(s), control, in terminal care, 1982: Sept., 1161–1168, 1169–1183 with drugs, 1982: Sept., 971–1083. See also under specific symptom.

gastrointestinal, in the terminally ill, 1982: Sept., 1174

Synovial fluid, infections, cephalosporins for, 1982: Jan., 186–188

Syphilis, 1982: July, 918–920; 1983: Jan., 244–245

Systemic disorders, lactic acidosis and, 1983: July, 821–822

renal tubular acidosis and, 1983: July, 872–873

Systemic lupus erythematosus, 1981: Sept., 1097. See also Lupus erythematosus, systemic.

TAENIASIS, 1982: May, 737-738

Takayasu's disease, 1982: July, 952Tamponade, balloon, for variceal bleeding, 1983: Nov., 1220–1221

cardiac, acute, 1981: Jan., 75-77

Tangier disease, 1982: March, 474–476 Tapeworm infection(s), 1982: May, 736–739 T-cell deficiency syndromes, 1982: May, 746

Tar products, in psoriasis, 1982: July, 779-781

Tardive dyskinesia, with antipsychotics, 1983: March, 370–371

with neuroleptics, 1982: Sept., 1004 Tartrazine, urticaria and, 1982: July, 835

Telangiectasia, steroid-induced, 1981: Sept., 1087

Terbutaline, 1981: May, 585–586 Terminal illness, anxiety in, 1982: Sept.,

1016 depression in, 1982: Sept., 1015 symptom control in, 1982: Sept.,

1161–1168, 1169–1183 Testes, disorders, in aged, 1983: March,

490–492 Test(ing), laboratory. See under *Laboratory*

and specific procedure.
Tetanus immunization, 1983: Jan., 28

Tetany, acute hypocalcemia with, 1981: March, 391

Tetracycline(s), 1982: Jan., 293–302; 1983: Jan., 70–71

for acne, 1982: July, 860-861

for lymphogranuloma venereum, 1982: July, 924

for nongonococcal ure thritis, 1982: July, 918

for perioral dermatitis, 1982: July, 821-822

Tetracycline(s) (Continued) for rosacea, 1982: July, 824-825 resistance to, 1982: Jan., 33

Tetracycline hydrochloride, for intestinal protozoan infections, 1982: May, 718 Thalidomide, for pruritus, 1982: Sept.,

1125-1126

Thallium-201 cardiac imaging, in right ventricular enlargement, 1981: May, 500 Theophylline, 1981: May 587-597; 1981:

Sept., 1038

in cor pulmonale, 1981: May, 513 Thiabendazole, for parasitic infections, 1982:

Jan., 251 Thoracic aorta, aneurysms of, 1981: Jan., 83-86

Thoracic restrictive disease, respiratory muscle fatigue in, 1983: May, 587-588

Throat cultures, 1983: Jan., 42-44 Thrombocyte(s). See Platelet(s).

Thrombocytopenia, as drug reaction, 1981: Sept., 1098 in acute respiratory failure, 1983: May,

738-739

Thromboembolic disorders, prostaglandins and, 1981: July, 870-874

radiographic features of, 1983: Nov., 1315-1316

with respiratory failure, 1983: Nov., 1179-1191

Thrombolytic agent(s), for pulmonary embolism 1983: Nov., 1185-1187

Thrombosis, arachidonic acid metabolites and, 1981: July, 867-870

of cavernous sinus, 1983: Jan., 148 Thromboxane(s), in septic lung injury, 1983: May, 703-704

Thrush, oral, 1982: July, 884

Thymidine kinase, role in herpes infection, 1983: Sept., 1142-1143

Thymus gland, involution, aging and, 1983: March, 263

Thyroid function, tests of, 1983: March, 498-499

Thyroid gland, cancer of, in aged, 1983: March, 510-512

disorders, in aged, 1983: March, 497-516 Thyroid hormone(s), levels, in diagnosis of

hyperthyroidism, 1983: March, 501-502 in diagnosis of hypothyroidism, 1983:

March, 506-507

Thyroid storm, 1983: Nov., 1202-1203 D-Thyroxine, for hypercholesterolemia, 1982: March, 544-545

Ticarcillin, 1982: Jan., 61-73 resistance to, 1982: Jan., 64 Ticrynafen, 1981: March, 295

Tinea barbae, 1982: July, 880 capitis, 1982: July, 881 corporis, 1982: July, 882-884 Tinea (Continued)

cruris, 1982: July, 880 pedis, 1982: July, 878-880

profunda, 1982: July, 880-881 unguium, 1982: July, 881-882

versicolor, 1982: July, 877-878

Tinidazole, for intestinal protozoan infections, 1982: May, 718

Tissue oxygenation, assessment of, 1983: May. 569

Tissue penetration, antimicrobial, 1982: Jan., 39-49 factors influencing, 1982: Jan., 40-43

models of, 1982: Jan., 43-48

Tolerance, to antimicrobials, overcoming, 1982: Jan., 19-20 to morphine, 1982: Sept., 1065-1066 to narcotics, 1982: Sept., 1100-1101

Tolmetin, for pain, 1982: Sept., 1056

Tomography, computed, in herpes simplex encephalitis, 1983: Sept., 977-998 Tourette's syndrome, neuroleptics for, 1982:

Sept., 1005 Toxic epidermal necrolysis, 1981: Jan., 232;

1981: Sept., 1098 Toxicity, decreased, in combination antimi-

crobial therapy, 1982: Jan., 21 of benzodiazepines, 1982: Sept., 1018-1021

of digitalis, in aged, 1982: Sept., 1076-1077

Toxic reactions, to drugs, in aged, 1983: March, 325-326, 383-384

Trachoma, 1983: Jan., 143

Traffic accidents, benzodiazepines and, 1982: Sept., 1021

Training, exercise, in chronic obstructive lung disease, 1981: May, 541-543

Transhepatic embolization (THE), percutaneous, for variceal bleeding, 1983: Nov., 1221

Transient ischemic attack(s), in aged, 1983: March, 354-355, 390-391 prostaglandins and, 1981: July, 872

Trauma, coma after, 1981: Jan., 20 respiratory distress syndrome after, 1981: Jan., 34

Traveler's diarrhea, prophylaxis, 1983: Jan., 108, 213-219

Tretinoin, in acne, 1982: July, 856-857 Triamcinolone, for asthma, 1981: May, 602

Triamterene, 1981: March, 296 Trichomoniasis, 1983: Jan., 228-229 metronidazole for, 1982: Jan., 124

Trichuriasis, 1982: May, 735-736

Tricyclic antidepressants, for depression, 1982: Sept., 1037-1045 for insomnia, 1982: Sept., 977

in aged, 1983: March, 372 overdose, management of, 1983: Nov., 1287-1288

Tricyclic antidepressants (Continued) side effects of. 1982: Sept., 1040–1043 Trifluridine, 1983: Sept., 973–974, 1164 Triflurothymidine. See Trifluridine.

Triglycerides, overproduction of, in hypertriglyceridemia, 1992: March, 522–523 plasma, atherosclerosis and, 1982: March, 519–522

Trimethoprim, 1982: Jan., 151; 1983: Jan., 72-75

resistance to, 1982: Jan., 34

Trimethoprim-sulfamethoxazole, 1982: Jan., 143–156; 1983: Jan., 72–74

for intestinal protozoan infections, 1982: May, 718

for shigellosis, 1982: May, 635

Tropical eosinophilia, 1981: Sept., 1066 Tropical sprue, 1982: May, 567–569

Tuberculosis, 1983: Nov., 1243
 antimicrobials for, 1982: Jan., 209–219
 drug therapy, 1983: Jan., 80–83
 in aged, 1983: March 428–429

outpatient therapy, 1983: Jan., 183–184 prophylaxis, 1983: Jan., 104–106

Tuberculous meningitis, 1982: May, 755–762Tubulointerstitial disease(s), acute renal failure and, 1983: Nov., 1328–1331

Tularemia, pneumonia and, 1983: Nov., 1241-1242

Tumor(s). See also Carcinoma and specific types and regions.

endocrine crisis and, 1983: Nov., 1210–1212

hormone-secreting, secretory diarrheas due to, 1982: May, 605-609 intracranial, 1981: Jan., 21-25 lactic acidosis and, 1983: July, 821-822 metastatic, prostaglandins and, 1981: July,

virus-associated, 1983: Sept., 1105–1127 Tumoral calcinosis, 1981: March, 397 Twin studies, of diabetes, 1982: Nov.,

1220-1222 Tyramine, urticaria and, 1982: July, 835-836 Uremia. See also Renal failure, chronic. pruritus in, 1982: Sept., 1127-1128

Urethral discharge, laboratory examination, 1983: Jan., 51-52, 240

Urethritis, 1983: Jan., 240-242

nongonococcal, 1982: July, 917–918; 1983: Sept., 1067

tetracyclines for, 1982: Jan., 299–300 Uric acid metabolism, clinical disorders of, 1981: March, 401–411

Urinary tract, disorders, in aged, 1983: March, 445–461

infections, 1983: Jan., 187-201

antimicrobials for, 1982: Jan., 199–208. See also specific agent, such as Nitrofurantoin.

in aged, 1983: March, 284–285, 452–453

prophylaxis, 1983: Jan., 108–109 recurrent, 1983: Jan., 195–197 tetracyclines for, 1982: Jan., 299 trimethoprim-sulfamethoxazole for, 1982: Jan., 147

Urine, acidification of. See Acidification,

analysis of, in renal failure, 1983: Nov., 1334–1335

glucose levels, in dianosis of diabetes, 1982: Nov., 1199

specimens, 1983: Jan., 46–48 Urokinase, for pulmonary embolism, 1983: Nov., 1186–1187

Uropathy, obstructive, 1981: March, 415-416

Urticaria, drug-induced, 1981: Sept., 1092
 solar, 1982: July, 933–934
 treatment of, 1982: July, 831–849

Uterus, infections, cephalosporins for, 1982: Jan., 189–191

prostaglandin production by, 1981: July, 930

Uveal tract, infections, 1983: Jan., 149–150 Uveitis, 1983: Jan., 149–150

ULCER(s), corneal, 1983: Jan., 144–145 epithelial, in recurrent herpes infection, 1983: Sept., 977–978

gastric, bleeding from, 1983: Nov., 1222–1225

genital, 1983: Jan., 242–246 peptic, in aged, 1983: March, 437 pudendal, 1982: July, 921–922 stasis, in aged, 1983: March, 534–535

Ulcerative colitis, in aged, 1983: March, 442–443

Ultraviolet light, for pruritus, 1982: Sept., 1127–1128 for psoriasis, 1982: July, 781–783 VACCINATION, against infectious disease, 1983: Jan., 17–38. See also specific diseases, as Smallpox vaccine.

Vaccine(s), adverse reactions to, 1983: Jan., 17-21

components of, 1983: Jan., 21–24 viral, 1983: Sept., 1020–1021, 1041, 1129–1145

in immunocompromised host, 1983: Sept., 1085–1087

Vaccinia, ocular, 1983: Sept., 988–989 Vaccinia virus, recombinant, 1983: Sept., 1143–1144

Vaginal discharge, laboratory examination, 1983: Jan., 48–49

Vaginitis, nonspecific, 1983: Jan., 230-231 metronidazole for, 1982: Jan., 124

Vancomycin, 1982: Jan., 175-181

for antibiotic-associated pseudomembranous colitis, 1982: May, 660-661

Varicella-zoster virus infection(s), 1982: July, 810-812

in immunocompromised host, 1983: Sept., 1083-1084

Varices, bleeding esophageal, 1983: Nov., 1219-1222

Vascular disease, in aged, 1983: March, 354-355

hemorrhage with, 1981: Jan., 137 intestinal, in aged, 1983: March, 438-440 renal failure and, 1983: Nov., 1332-1333

Vasculitis, drug-induced, 1981: Sept., 1094 leukocytoclastic, 1982: July, 942-947 treatment of, 1982: July, 941-954 urticarial, 1982:July, 836-840

Vasoactive substances, prostaglandins and, 1981: July, 881-889

Vasodilators, effects, in diabetics, 1982: Nov., 1381

in cor pulmonale, 1981: May, 514 Vasopressin, for variceal bleeding, 1983: Nov., 1220

prostaglandin synthesis and, 1981: July, 915-918

Vectorcardiography, in right ventricular enlargement, 1981: May, 500

Venereal disease(s), in men, 1983: Jan., 235-251

in women, 1983: Jan., 221-234 prophylaxis, 1983: Jan., 102 tetracyclines for, 1982: Jan., 299-300 treatment of, 1982: July, 915-925 viral, 1983: Sept., 1059-1073 in homosexual men, 1983: Sept.,

1093-1104

Venereal warts, 1983: Sept., 1064-1065 Venous pressure, central, monitoring of, in critically ill, 1983: Nov., 1348

Ventilation, alveolar, abnormality of, 1983: May, 558

maintenance of, in acute respiratory failure, 1983: May, 614-615 continuous positive pressure, cardiovascu-

lar function and, 1983: May, 626-627 high-frequency, 1983: May, 633-643 intermittent mandatory, 1983: May, 600-604

physiology of, 1983: May, 624 mechanical, cardiovascular function and, 1983: May, 626-627

in acute respiratory failure, 1983: May, 593, 599-619, 663-664 in ARDS, 1983: May, 693 physiology of, 1983: May, 621-631 withdrawal from, 1983: May, 617-619,

664-665

Ventilation (Continued)

spontaneous, physiology of, 1983: May, 622-623

synchronized intermittent mandatory. 1983: May, 605-606, 611

Ventilation—perfusion imbalance, 1983: May, 559-560

Ventilator(s), mechanical. types of, 1983: May. 599-619

Ventilatory requirements, 1981: May, 528-530

in chronic obstructive lung disease, 1981: May 532-535

Ventilatory response, during exercise, 1981: May, 526-528

Verruca. See Wart.

Vertigo, in aged, 1983: March, 353-354 Very low density lipoproteins (VLDL), 1982: March, 520

relation to high density lipoproteins, 1982: March, 521-522

relation to low density lipoproteins, 1982: March, 521

Very low density lipoprotein remnants, 1982: March, 520-521

β-Very low density lipoproteins, 1982: March, 390-397

atherosclerosis and, in dogs, 1982: March, 393-395

in cholesterol-fed man, 1982: March, 395 Vibrio cholerae, 1982: May, 598-602, 611-612, 666-668

Vibrio infection(s), 1982: May, 665-673 Vidarabine, 1983: Sept., 973-974 for viral infections, 1982: Jan., 238-240

in herpes infections, 1983: Sept., 999-1004, 1165-1166

in immunocompromised host, 1983: Sept.,

Viral arthritis, 1981: Jan., 181

Viral gastroenteritis, 1982: May, 575-595 Viral infection(s), cutaneous, 1982: July, 807-817

diabetes and, 1982: Nov., 1213-1214 drug therapy for, 1983: Sept., 1163-1172 enteric, 1983: Sept., 1031-1058 in aged, 1983: March, 287-289

in immunocompromised host, 1983: Sept., 1075-1092 laboratory diagnosis of, 1983: Sept.,

935-951, 953-972 ocular, 1983: Sept., 973-990 pneumonia and, 1983: Nov., 1235, 1246 respiratory, 1983: Sept., 1009-1030 venereal, 1983: Sept., 1059-1073

in homosexual men, 1983: Sept., 1093-1104

Viral serology, 1983: Sept., 944-948, 963-966

Virology, medical, symposium on, 1983: Sept., 935-1172

Virus(es), as vaccines, 1983: Sept., 1129–1145

determination of immunity to, 1983: Sept., 965–966

drugs for, 1982: Jan., 235–244 herpes zoster, 1982: Sept., 1107–1108 in enhancing airway reactivity, 1981:

Sept., 1048–1051 infections. See Viral infection(s). laboratory diagnosis of, 1983: Sept.,

935–951, 953–972 oncogenic, 1983: Sept., 1105–1127 Visceral aneurysm, 1981: Jan., 94

Visceral aneurysm, 1981: Jan., 94 Vitamin A, for acne, 1982: July, 856–857, 863–866

for psoriasis, 1982: July, 788 for rosacea, 1981: July, 826

Vitamin D-resistant rickets, 1981: March, 394

VLDL. See Very low density lipoproteins (VLDL).

Vulvovaginitis, 1983: Jan., 228-231

Wart(s), treatment of, 1982: July, 812–814 Water. See also Body water.

balance, in respiratory failure, 1983: May, 654–655

diuresis, 1981: March, 310-313 intoxication, acute, 1981: March, 263

Weakness, in aged, 1983: March, 356–358 Wegener's granulomatosis, 1982: July, 948–949

Weight, excess. See Obesity. loss, in aged, 1983: March, 337 Wheezing, in aged, 1983: March, 337–338 White blood cell(s). See Leukocyte(s).

White classification, to assess fetal risk in diabetics, 1982: Nov., 1325

Wiskott-Aldrich syndrome, 1981: Sept., 967 Wound healing, in aged, 1983: March, 536–537

XANTHOMATOSIS, in familial dysbetalipoproteinemia, 1982: March, 450

in monogenic hyperlipidemias, 1982: March, 330-331

planar, with high density lipoprotein deficiency, 1982: March, 479

Xerosis, of skin, in aged, 1983: March, 535–536

YEAST, in diet, urticaria and, 1982: July, 835–836

Yersinia enteritis, 1982: May, 639–653 endoscopic features, 1982: May, 647, 651 radiologic examination for, 1982: May, 646–650

relationship with idiopathic inflammatory bowel disease, 1982: May, 643 treatment, 1982: May, 647–650

ZINC, deficiency, in aged, 1983: March, 306–307

Zollinger-Ellison syndrome, secretory diarrhea in, 1982: May, 607–609 Zomepirac, for pain, 1982: Sept., 1056

Statement of Ownership, Management, and Circulation (Act of August 12, 1970; Section 3685, Title 39, United States Code)

1. Date of filing: September 15, 1983.

Title of publication: The Medical Clinics of North America

Frequency of issue: Bi-monthly.

Location of known office of publication: Hampton Road, Cherry Hill, New Jersey 08002.

Location of the headquarters or general business offices of the publisher: West Washington Square,

Philadelphia, Pa. 19105.

Names and addresses of publisher, editor, and managing editor: Publisher, W. B. Saunders Company, a division of CBS, Inc., West Washington Square, Philadelphia, Pa. 19105; Editor, Kay Dowgun, c/o W. B. Saunders Company, West Washington Square, Philadelphia, Pa. 19105; Managing Editor,

none.

7. Holders of record of 1% or more of CBS voting stock as of June 30, 1983: Bank of New York, 110 Washington Street, New York, NY 10015; Bankers Trust Company, P.O. Box 704, Church Street Station, New York, NY 10015; Boston Safe Deposit & Trust Company, P.D. Boxton Place, Boston, MA 02106; Bradford Trust Company, 70 Pine Street, New York, NY 10005; Chase Manhattan Bank, 1 Chase Manhattan Plaza, New York, NY 10015; Citibank N.A., 111 Wall Street, New York, NY 10045; Depository Trust Company, 55 Water Street, New York, NY 10041; First National Bank of Boston, P.O. Box 2016, Station 9-FA, Boston, MA 02106; First National Bank of St. Paul, 332 Minnesota Street, St. Paul, MN 55101; Hartford National Bank & Trust, 777 Main Street, Hartford, CT 06115; Irving Trust Company, One Wall Street, New York, NY 10015; Manufacturers Hartford, CT 06115; Chicago, IL Go603; Morgan Guaranty Trust Company, 37 Widwest Securities Trust Company, 120 S. LaSalle Street, Chicago, IL Go603; Morgan Guaranty Trust Company, 37 Wall Street, Work, NY 10005.

pany, 660 Fifth Avenue, New York, NY 10020; Midwest Securities Trust Company, 120 S. LaSalle Street, Chicago, IL 60603; Morgan Guaranty Trust Company, 37 Wall Street, New York, NY 10005; Northern Trust Company, 50 S. LaSalle Street, Chicago, IL 60690; Pacific Securities Depositary, Trust Company, 30 Pine Street, San Francisco, CA 94104; William S. Paley, 51 West 52nd Street, New York, NY 10019; Security Pacific Bank, 333 South Hope Level E. Los Angeles, CA 90051; State Street Bank & Trust Company, 225 Franklin Street, Boston, MA 02105.
Holders of 1% or more of CBS 14½ notes as of July 19, 1982; Amalgamated Bank of New York, 1115 Union Square, New York, NY 10003; Bankers Trust Company, P.O. Box 704, Church Street Station, New York, NY 10015; Bank of New York, P.O. Box 11203, Church Street Street Station, New York, NY 10014; Didwest Stock Exchange, Clearing Corporation, 120 S. LaSalle Street, Chicago, IL 60603; Omaha National Bank, Farham at 17th, Omaha, NE 68102. Holders of 1% or more of CBS 7.85% debentures as of July 15, 1982; Depository Trust Company, P.O. Box 2054, Allwaukee, WI 53201; Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Taragraphs 7 and 8 include, in cases in which the stockbalder or securities building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, Texas County & District Retirement System, 802 Perry Brooks Building, Austrun, P.O. Box 2054, Allwaukee, WI 53201; Texas County & Dist

10.

Paragraphs 7 and 8 include, in cases in which the stockholder or security holder appears upon the books of the company as a trustee or in any other fiduciary relation, the name of the person or corporation for whom such trustee is acting. Also the statements in the three paragraphs show the affiant's full knowledge and belief as to the circumstances and conditions under which stockholders and security holders who do not appear upon the books of the company as trustees hold stock and eccurities in a capacity other than that of a bona fide owner. Names and addresses of individuals who are stockholders of a corporation which itself is a stockholder or holder of bonds, mortgages, or other securities of the publishing corporation have been included in paragraphs 7 and 8 when the interests of such individuals are equivalent to 1 per cent or more of the total amount of the stock or securities of the publishing

corporation.			
	Av. No. Copies Each Issue During Preceding 12 Mos.	Single Issue Nearest to Filing Date	
A. Total number of copies printed (net press run)	49,000	48,000	
B. Paid circulation			
Sales through dealers and carriers, street vendors, and counter sales			
2. Mail subscriptions	41.410	40,890	
C. Total paid circulation	41,410	40.890	
D. Free distribution by mail, carrier or other means			
 Samples, complimentary, and other free copies Copies distributed to news agents, but not sold 	100	100	
E. Total distribution (sum of C and D)	41.510	40,990	
F. Office use, left-over, unaccounted, spoiled after printing	7.490	7.010	
G. Total (sum of E and F-should equal net press run shown	49,000	49,000	

I certify that the statements made by me above are correct and complete.



